

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau**INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

(51) International Patent Classification ⁷ : A61L 31/10, 31/16, A61F 2/06		A1	(11) International Publication Number: WO 00/40278 (43) International Publication Date: 13 July 2000 (13.07.00)		
(21) International Application Number: PCT/CA99/01237			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).		
(22) International Filing Date: 30 December 1999 (30.12.99)					
(30) Priority Data: 60/114,731 31 December 1998 (31.12.98) US 60/116,726 20 January 1999 (20.01.99) US					
(71) Applicants (<i>for all designated States except US</i>): ANGIOTECH PHARMACEUTICALS, INC. [CA/CA]; 6660 Northwest Marine Drive, Vancouver, British Columbia V6T 1Z4 (CA). UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; IRC 331-2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA).					
(72) Inventors; and					
(75) Inventors/Applicants (<i>for US only</i>): MACHAN, Lindsay, S. [CA/CA]; 3670 Cameron Avenue, Vancouver, British Columbia V6R 1A2 (CA). JACKSON, John, K. [CA/CA]; 4001 West 33rd Avenue, Vancouver, British Columbia V6N 2H9 (CA). HUNTER, William, L. [CA/CA]; 525 Penticton Street North, Vancouver, British Columbia V5K 3L7 (CA).					
(74) Agents: NASSIF, Omar, A. et al.; Gowling, Strathy & Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).					

(54) Title: STENT GRAFTS WITH BIOACTIVE COATINGS

(57) Abstract

Stent grafts are provided comprising an endoluminal stent and a graft, wherein the stent graft releases an agent which induces the *in vivo* adhesion of the stent graft to vessel walls, or, otherwise induces or accelerates an *in vivo* fibrotic reaction causing said stent graft to adhere to vessel wall. Also provided are methods for making and using such stent grafts.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

STENT GRAFTS WITH BIOACTIVE COATINGS

TECHNICAL FIELD

The present invention relates generally to pharmaceutical compositions, methods and devices, and more specifically, to compositions and methods for preparing 5 stent grafts to make them more adherent to, or, more readily incorporated within a vessel wall.

BACKGROUND OF THE INVENTION

Stent grafts have been developed in order to not only simply hold open a passageway, but also to bridge across diseased vasculature from healthy vessel to 10 healthy vessel. The most common application of stent grafts is to bypass an abdominal aortic aneurysm (AAA). Briefly, a stent graft is inserted over a guide wire, from the femoral or iliac artery and deployed within the aneurysm, resulting in maintenance of blood flow from an aorta of acceptable (usually normal) caliber above to a portion of aorta or iliac artery(s) of acceptable (usually normal) caliber below the aneurysm. The 15 aneurysm sac is thus excluded. Blood within this excluded sac thromboses and the aneurysm thus has no flow within it, presumably reducing the pressure and thus its tendency to burst.

Presently available stent grafts however have a number of problems. For example, current stent grafts are prone to persistent leakage around the area of the stent 20 graft. Hence, pressure within the sac stays at or near arterial pressure and there is still a risk of rupture. There are 3 common types of perigraft leakage. The first type is direct leakage around the stent graft. This can be persistent from the time of insertion because of poor sealing between the stent graft and vessel wall, or can develop later because the seal is lost. In addition, this problem can develop due to changes in the position or 25 orientation of the stent graft in relation to the aneurysm as the aneurysm grows, shrinks, elongates or shortens with time after treatment. The second type of perigraft leak can occur because there are side arteries extending out the treated segment of blood vessel. Once the aneurysm is excluded by the device, flow can reverse within these blood vessels and continue to fill the aneurysm sac around the stent graft. The third type of

perigraft leak can occur because of disarticulation of the device (in the case of modular devices) or because of the development of holes within the graft material because continuous pulsation of the vessel causes the graft material to rub against a metallic stent tyne eventually causing graft failure. Disarticulation of the device can develop 5 due to changes in shape of the aneurysm as it grows, shrinks, elongates or shortens with time after treatment.

Stent grafts are also limited in their application to only selected patients with aneurysms. For example, endovascular stents are an advance in the treatment of AAA as they offer the avoidance of standard therapy, which is a major operation with a 10 significant morbidity, mortality, long hospital stays, and prolonged recovery time. However, endovascular technology is only applicable to certain patients with AAA because (a) lack of a suitable route of access via the blood vessels to the intended site of deployment which prevents insertion of the device and (b) anatomy.

More specifically, in order to exclude an aneurysm, the graft material 15 needs to be of a certain strength and durability or it will tear. Typically, this implies a Dacron or PTFE graft material of conventional "surgical" thickness as thickness is one parameter to convey strength to the material. The thickness in the graft portion of the device results in the need for delivery devices which can be up to 32 French (10.67mm diameter). This almost always requires surgical exposure of the insertion site, usually a 20 common femoral artery and limits the application of the technology as a larger delivery device is more difficult to manipulate through the iliac artery to the intended site of delivery. Even "low profile" devices which use thinner graft material still are of a sufficient size that a surgical exposure of the blood vessel through which the device is inserted is almost always required. If the iliac arteries or aorta are very tortuous, 25 (frequently the case in AAA), or heavily calcified and diseased (another frequent association with AAA), this may be a contraindication to treatment or cause of failure of attempted treatment because of inability to advance a device to the site of deployment or potential for iliac artery rupture.

Furthermore, a stent graft typically bridges a diseased artery (usually an 30 aneurysm) extending from a portion of artery of acceptable caliber above to acceptable caliber below. To achieve a long lasting seal the artery of acceptable caliber above

(“proximal neck”) should be at least 1.5 cm long without a major branch vessel arising from it, and the artery of acceptable caliber below (“distal neck”) should be at least 1.0 cm long without a major branch vessel arising within that 1 cm. Shorter “necks” at either end of the diseased segment, necks which are sloping rather than cylindrical, or 5 necks which are smaller than the aneurysm but still dilated in comparison to the normal diameter for a vessel in this location predispose to failure of sealing around the stent graft or delayed perigraft leaks.

One further difficulty with present stent grafts is that over time certain devices have a tendency to migrate distally within the abdominal aorta. Such migration 10 results in device failure, perigraft leak and vessel occlusion.

Finally, there is long term uncertainty about the entire stent graft technology as a treatment for AAA. Standard open aneurysm repair is extremely durable. Uncertainties about endovascular stent grafts include whether they will lower the aneurysm rupture rate, rate of perigraft leak, device migration, ability to effectively 15 exclude aneurysms over a long term, and device rupture or disarticulation.

The present invention discloses novel compositions, methods for preparing, and devices related to stent grafts, and further provides other related advantages.

SUMMARY OF THE INVENTION

20 Briefly stated, the present invention provides stent grafts, compositions for coating stent grafts, as well as methods for making and using these grafts. Within one aspect of the invention stent grafts are provided which induce adhesion or fibrosis in vessel walls, thus increasing or accelerating adherence of the stent graft to the vessel wall. Within various embodiments, such adhesion or fibrosis is induced by release of 25 an agent from the stent graft.

Within related aspects of the present invention, stent grafts are provided comprising an endoluminal stent and a graft, wherein the stent graft releases an agent which induces the *in vivo* adhesion of the stent graft to vessel walls. As utilized herein, “induces adhesion to vessel walls” should be understood to refer to agents or 30 compositions which increase or accelerates a reaction between the stent graft and the

vessel wall, such that the position of the stent graft is fixed within the vessel. "Release of an agent" refers to any statistically significant presence of the agent, or a subcomponent thereof, which has disassociated from the stent graft.

Within a related aspect, stent grafts are provided comprising an
5 endoluminal stent and a graft, wherein the stent graft induces or accelerates an *in vivo* fibrotic reaction causing the stent graft to adhere to vessel wall.

Within related aspects, stent grafts are constructed so that the graft itself is comprised of materials, which induce adhesion or fibrosis with vessel walls.

Within various embodiments of the invention, the stent graft is coated
10 with a composition or compound, which delays the onset of adhesion or fibrosis. Representative examples of such agents include heparin, PLGA/MethylPEG, PLA, and polyethylene glycol. Within further embodiments the stent graft is activated prior to use (e.g., the agent is first activated from a previously inactive agent to an active agent, or, the stent graft is activated from a previously inactive stent graft to one that induces
15 or accelerates an *in vivo* fibrotic reaction.). Such activation may be accomplished either before insertion, during insertion, or, subsequent to insertion.

Within one embodiment of the invention, the stent graft is adapted to release a vessel wall irritant. Representative examples of such irritants talcum powder, metallic beryllium, and silica. Other agents which may be released by the stent graft
20 include components of extracellular matrix, fibronectin, polylysine, ethylenevinylacetate, and inflammatory cytokines such as TGF β , PDGF, VEGF, bFGF, TNF α , NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone, and adhesives such as cyanoacrylate.

A wide variety of stent grafts may be utilized within the context of the
25 present invention, depending on the site and nature of treatment desired. Stent grafts may be, for example, bifurcated or tube grafts, cylindrical or tapered, self-expandable or balloon-expandable, unibody, or, modular. Moreover, the stent graft may be adapted to release the desired agent at only the distal ends, or along the entire body of the stent graft.

30 Also provided by the present invention are methods for treating patients having aneurysms (e.g., abdominal, thoracic, or iliac aortic aneurysms), for bypassing a

diseased portion of a vessel, or for creating communication or a passageway between one vessel and another (e.g., artery to vein or vice versa, or artery to artery or vein to vein), such that risk of rupture of the aneurysm is reduced. As utilized herein, it should be understood that 'reduction in the risk of rupture' or 'prevention of the risk of 5 rupture' refers to a statistically significant reduction in the, number, timing, or, rate of rupture, and not to a permanent prohibition of any rupture.

Within yet other aspects of the present invention methods are provided for manufacturing stent grafts, comprising the step of coating (e.g., spraying, dipping, or, wrapping) a stent graft with an agent which induces adhesion of the stent graft to 10 vessel walls (including for example, induction of an in vivo fibrotic reaction with vessel walls). Within related aspects, the stent graft can be constructed with materials, which release, or, by themselves induce adhesion or fibrosis with vessel walls.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, 15 various references are set forth herein which describe in more detail certain procedures or compositions, and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration of one representative stent graft. Dashed lines indicate coating of the graft with a desired agent at each end of the graft. 20 Figure 2 is a cross-sectional view of the stent graft illustrated in Figure 1.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

Prior to setting forth the invention, it may be helpful to an understanding thereof to first set forth definitions of certain terms that is used hereinafter.

25 "Stent graft" refers to devices comprising a graft or wrap (composed of a textile, polymer, or other suitable material such as biological tissue) which maintains the flow of fluids (e.g., blood) from one portion of a vessel to another, and an endovascular scaffolding or stent which holds open a body passageway and/or supports

the graft or wrap. The graft or wrap may be woven within a stent, contained within the lumen of a stent and/or exterior to a stent.

As discussed above, the present invention provides compositions, 5 methods and devices relating to stent grafts, which greatly increase the success and application of stent grafts. In particular, such stent grafts can accelerate or enhance occlusion of the lumen of the blood vessel outside the stent graft, and increase the strength and durability of the graft portion of the device.

Described in more detail below are methods for constructing stent 10 grafts, compositions and methods for generating stent grafts which adhere to a vessel wall, and methods for utilizing such stent grafts.

Construction of Stent Grafts

As noted above, stent grafts refers to devices comprising a graft or wrap which maintains the flow of fluids (*e.g.*, blood) from one portion of a vessel to another, 15 or from one blood vessel to another, and an endovascular scaffolding or stent which holds open a body passageway and/or supports the graft or wrap. One representative stent graft is illustrated in Figures 1 and 2.

The graft portion of the stent may be composed of a textile, polymer, or other suitable material such as biological tissue. Representative examples of suitable 20 graft materials include textiles such as nylon, Orlon, Dacron, or woven Teflon, and non-textiles such as expanded polytetrafluoroethylene (PTFE). The graft or wrap may be woven within a stent, contained within the lumen of a stent and/or exterior to a stent.

The endovascular scaffolding or stent is adapted to hold open a body passageway and/or support the graft or wrap. Representative examples of stent grafts, 25 and methods for making and utilizing such grafts are described in more detail in U.S. Patent No. 5,810,870 entitled "Intraluminal Stent Graft"; U.S. Patent No. 5,776,180 entitled "Bifurcated Endoluminal Prosthesis"; U.S. Patent No. 5,755,774 entitled "Bistable Luminal Graft Endoprosthesis"; U.S. Patent Nos. 5,735,892 and 5,700,285 entitled "Intraluminal Stent Graft"; U.S. Patent No. 5,723,004 entitled "Expandable 30 Supportive Endoluminal Grafts"; U.S. Patent No. 5,718,973 entitled "Tubular

Intraluminal Graft"; U.S. Patent No. 5,716,365 entitled "Bifurcated Endoluminal Prosthesis"; U.S. Patent No. 5,713,917 entitled "Apparatus and Method for Engrafting a Blood Vessel"; U.S. Patent No. 5,693,087 entitled "Method for Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,683,452 entitled "Method for
5 Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,683,448 entitled "Intraluminal Stent and Graft"; U.S. Patent No. 5,653,747 entitled "Luminal Graft Endoprostheses and Manufacture Thereof"; U.S. Patent No. 5,643,208 entitled "Balloon Device of Use in Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,639,278 entitled "Expandable Supportive Bifurcated Endoluminal Grafts"; U.S.
10 Patent No. 5,632,772 entitled "Expandable Supportive Branched Endoluminal Grafts"; U.S. Patent No. 5,628,788 entitled "Self-Expanding Endoluminal Stent-Graft"; U.S. Patent No. 5,591,229 entitled "Aortic Graft for Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,591,195 entitled "Apparatus and Methods for Engrafting a Blood Vessel"; U.S. Patent No. 5,578,072 entitled "Aortic Graft and Apparatus for
15 Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,578,071 entitled "Aortic Graft"; U.S. Patent No. 5,571,173 entitled "Graft to Repair a Body Passageway"; U.S. Patent No. 5,571,171 entitled "Method for Repairing an Artery in a Body"; U.S. Patent No. 5,522,880 entitled "Method for Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,405,377 entitled "Intraluminal Stent"; and U.S. Patent No. 5,360,443
20 entitled "Aortic Graft for Repairing an Abdominal Aortic Aneurysm".

Compositions and Methods for Generating Stent Grafts
which Adhere to a Vessel Wall

Stent grafts of the present invention are coated with, or otherwise adapted to release an agent which induces adhesion to vessel walls. Stent grafts may be
25 adapted to release such an agent by (a) directly affixing to the implant or device a desired agent or composition (e.g., by either spraying the stent graft with a polymer/drug film, or by dipping the implant or device into a polymer/drug solution, or by other covalent or noncovalent means); (b) by coating the stent graft with a substance such as a hydrogel which will in turn absorb the desired agent or composition; (c) by
30 interweaving agent or composition coated thread into the stent graft (e.g., a polymer

which releases the agent formed into a thread) into the implant or device; (d) by inserting a sleeve or mesh which is comprised of or coated with the desired agent or composition; (e) constructing the stent graft itself with the desired agent or composition; or (f) otherwise impregnating the stent graft with the desired agent or composition. Suitable adhesion inducing agents may be readily determined based upon the animal models provided in Example 14 (Screening Procedure for Assessment of Perigraft Reaction) and Example 15 (Animal Abdominal Aortic Aneurysm Model).

Representative examples of adhesion inducing agents include irritants (e.g., talcum powder, metallic beryllium and silica), components of extracellular matrix (e.g., fibronectin); polymers (e.g., polylysine and ethylenevinylacetate); inflammatory cytokines (e.g., TGF β , PDGF, VEGF, bFGF, TNF α , NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone); and inflammatory microcrystals (e.g., crystalline minerals such as crystalline silicates). Other representative examples include Monocyte chemotactic protein, fibroblast stimulating factor 1, histamine, fibrin or fibrinogen, endothelin-1, angiotensin II, bovine collagen, bromocriptine, methylsergide, methotrexate, N-carboxybutyl chitosan, carbon tetrachloride, Thioacetamide, talcum powder, Metallic beryllium (or its oxides), Quartz dust, Polylysine, Fibrosin, and ethanol.

Optionally, within one embodiment of the invention a desired adhesion-inducing agent may be admixed with, blended with, conjugated to, or, otherwise modified to contain as a composition a polymer, which may be either biodegradable or non-biodegradable. Representative examples of biodegradable compositions include albumin, collagen, gelatin, hyaluronic acid, starch, cellulose (methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), casein, dextrans, polysaccharides, fibrinogen, poly(D,L-lactide), poly(D,L-lactide-co-glycolide), poly(glycolide), poly(hydroxybutyrate), poly(alkylcarbonate) and poly(orthoesters), polyesters, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene terephthalate), poly(malic acid), poly(tartronic acid), polyanhydrides, polyphosphazenes, poly(amino acids) and their copolymers (*see generally*, Illum, L., Davids, S.S. (eds.) "Polymers in Controlled Drug Delivery" Wright, Bristol, 1987;

Arshady, *J. Controlled Release* 17:1-22, 1991; Pitt, *Int. J. Phar.* 59:173-196, 1990; Holland et al., *J. Controlled Release* 4:155-0180, 1986). Representative examples of non-degradable polymers include poly(ethylene-vinyl acetate) ("EVA") copolymers, silicone rubber, acrylic polymers (polyacrylic acid, polymethylacrylic acid, 5 polymethylmethacrylate, polyalkylcyanoacrylate), polyethylene, polypropylene, polyamides (nylon 6,6), polyurethane, poly(ester urethanes), poly(ether urethanes), poly(ester-urea), polyethers (poly(ethylene oxide), poly(propylene oxide), Pluronics and poly(tetramethylene glycol)), silicone rubbers and vinyl polymers (polyvinylpyrrolidone, poly(vinyl alcohol), poly(vinyl acetate phthalate). Polymers 10 may also be developed which are either anionic (e.g., alginate, carrageenan, carboxymethyl cellulose and poly(acrylic acid), or cationic (e.g., chitosan, poly-L-lysine, polyethylenimine, and poly(allyl amine)) (see generally, Dunn et al., *J. Applied Polymer Sci.* 50:353-365, 1993; Cascone et al., *J. Materials Sci.: Materials in Medicine* 5:770-774, 1994; Shiraishi et al., *Biol. Pharm. Bull.* 16(11):1164-1168, 1993; 15 Thacharodi and Rao, *Int'l J. Pharm.* 120:115-118, 1995; Miyazaki et al., *Int'l J. Pharm.* 118:257-263, 1995). Particularly preferred polymeric carriers include poly(ethylene-vinyl acetate), polyurethanes, poly (D,L-lactic acid) oligomers and polymers, poly (L-lactic acid) oligomers and polymers, poly (glycolic acid), copolymers of lactic acid and 20 glycolic acid, poly (caprolactone), poly (valerolactone), polyanhydrides, copolymers of poly (caprolactone) or poly (lactic acid) with a polyethylene glycol (e.g., MePEG), and blends, admixtures, or co-polymers of any of the above. Other preferred polymers include polysaccharides such as hyaluronic acid, chitosan and fucans, and copolymers 25 of polysaccharides with degradable polymers.

All of the above polymers may be blended or copolymerized in various 25 compositions as required.

Polymeric carriers can be fashioned in a variety of forms, with desired release characteristics and/or with specific desired properties. For example, polymeric carriers may be fashioned to release a therapeutic agent upon exposure to a specific triggering event such as pH (see, e.g., Heller et al., "Chemically Self-Regulated Drug 30 Delivery Systems," in *Polymers in Medicine III*, Elsevier Science Publishers B.V., Amsterdam, 1988, pp. 175-188; Kang et al., *J. Applied Polymer Sci.* 48:343-354, 1993;

Dong et al.; *J. Controlled Release* 19:171-178, 1992; Dong and Hoffman, *J. Controlled Release* 15:141-152, 1991; Kim et al., *J. Controlled Release* 28:143-152, 1994; Cornejo-Bravo et al., *J. Controlled Release* 33:223-229, 1995; Wu and Lee, *Pharm. Res.* 10(10):1544-1547, 1993; Serres et al., *Pharm. Res.* 13(2):196-201, 1996; Peppas, 5 "Fundamentals of pH- and Temperature-Sensitive Delivery Systems," in Gurny et al. (eds.), *Pulsatile Drug Delivery*, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1993, pp. 41-55; Doelker, "Cellulose Derivatives," 1993, in Peppas and Langer (eds.), *Biopolymers I*, Springer-Verlag, Berlin). Representative examples of pH-sensitive polymers include poly(acrylic acid) and its derivatives (including for example, 10 homopolymers such as poly(aminocarboxylic acid); poly(acrylic acid); poly(methyl acrylic acid), copolymers of such homopolymers, and copolymers of poly(acrylic acid) and acrylmonomers such as those discussed above. Other pH sensitive polymers include polysaccharides such as cellulose acetate phthalate; hydroxypropylmethylcellulose phthalate; hydroxypropylmethylcellulose acetate 15 succinate; cellulose acetate trimellitate; and chitosan. Yet other pH sensitive polymers include any mixture of a pH sensitive polymer and a water-soluble polymer.

Likewise, polymeric carriers can be fashioned which are temperature sensitive (see, e.g., Chen et al., "Novel Hydrogels of a Temperature-Sensitive Pluronic Grafted to a Bioadhesive Polyacrylic Acid Backbone for Vaginal Drug Delivery," in 20 *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.* 22:167-168, Controlled Release Society, Inc., 1995; Okano, "Molecular Design of Stimuli-Responsive Hydrogels for Temporal Controlled Drug Delivery," in *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.* 22:111-112, Controlled Release Society, Inc., 1995; Johnston et al., *Pharm. Res.* 9(3):425-433, 1992; Tung, *Int'l J. Pharm.* 107:85-90, 1994; Harsh and Gehrke, *J. Controlled Release* 17:175-186, 1991; Bae et al., *Pharm. Res.* 8(4):531-537, 1991; Dinarvand and D'Emanuele, *J. Controlled Release* 36:221-227, 1995; Yu and Grainger, 25 "Novel Thermo-sensitive Amphiphilic Gels: Poly N-isopropylacrylamide-co-sodium acrylate-co-n-N-alkylacrylamide Network Synthesis and Physicochemical Characterization," Dept. of Chemical & Biological Sci., Oregon Graduate Institute of 30 Science & Technology, Beaverton, OR, pp. 820-821; Zhou and Smid, "Physical Hydrogels of Associative Star Polymers," Polymer Research Institute, Dept. of

Chemistry, College of Environmental Science and Forestry, State Univ. of New York, Syracuse, NY, pp. 822-823; Hoffman et al., "Characterizing Pore Sizes and Water 'Structure' in Stimuli-Responsive Hydrogels," Center for Bioengineering, Univ. of Washington, Seattle, WA, p. 828; Yu and Grainger, "Thermo-sensitive Swelling Behavior in Crosslinked N-isopropylacrylamide Networks: Cationic, Anionic and Ampholytic Hydrogels," Dept. of Chemical & Biological Sci., Oregon Graduate Institute of Science & Technology, Beaverton, OR, pp. 829-830; Kim et al., *Pharm. Res.* 9(3):283-290, 1992; Bae et al., *Pharm. Res.* 8(5):624-628, 1991; Kono et al., *J. Controlled Release* 30:69-75, 1994; Yoshida et al., *J. Controlled Release* 32:97-102, 1994; Okano et al., *J. Controlled Release* 36:125-133, 1995; Chun and Kim, *J. Controlled Release* 38:39-47, 1996; D'Emanuele and Dinarvand, *Int'l J. Pharm.* 118:237-242, 1995; Katono et al., *J. Controlled Release* 16:215-228, 1991; Hoffman, "Thermally Reversible Hydrogels Containing Biologically Active Species," in Migliaresi et al. (eds.), *Polymers in Medicine III*, Elsevier Science Publishers B.V., Amsterdam, 1988, pp. 161-167; Hoffman, "Applications of Thermally Reversible Polymers and Hydrogels in Therapeutics and Diagnostics," in *Third International Symposium on Recent Advances in Drug Delivery Systems*, Salt Lake City, UT, Feb. 24-27, 1987, pp. 297-305; Gutowska et al., *J. Controlled Release* 22:95-104, 1992; Palasis and Gehrke, *J. Controlled Release* 18:1-12, 1992; Paavola et al., *Pharm. Res.* 12(12):1997-2002, 1995).

Representative examples of thermogelling polymers, and their gelatin temperature (LCST (°C)) include homopolymers such as poly(N-methyl-N-n-propylacrylamide), 19.8; poly(N-n-propylacrylamide), 21.5; poly(N-methyl-N-isopropylacrylamide), 22.3; poly(N-n-propylmethacrylamide), 28.0; poly(N-isopropylacrylamide), 30.9; poly(N, n-diethylacrylamide), 32.0; poly(N-isopropylmethacrylamide), 44.0; poly(N-cyclopropylacrylamide), 45.5; poly(N-ethylmethacrylamide), 50.0; poly(N-methyl-N-ethylacrylamide), 56.0; poly(N-cyclopropylmethacrylamide), 59.0; poly(N-ethylacrylamide), 72.0. Moreover thermogelling polymers may be made by preparing copolymers between (among) monomers of the above, or by combining such homopolymers with other water-soluble polymers such as acrylmonomers (e.g., acrylic acid and derivatives thereof such as

methylacrylic acid, acrylate and derivatives thereof such as butyl methacrylate, acrylamide, and N-n-butyl acrylamide).

Other representative examples of thermogelling polymers include cellulose ether derivatives such as hydroxypropyl cellulose, 41°C; methyl cellulose, 5 55°C; hydroxypropylmethyl cellulose, 66°C; and ethylhydroxyethyl cellulose, and Pluronics such as F-127, 10 - 15°C; L-122, 19°C; L-92, 26°C; L-81, 20°C; and L-61, 24°C.

Therapeutic agents may be linked by occlusion in the matrices of the polymer, bound by covalent linkages, or encapsulated in microcapsules. Within certain 10 preferred embodiments of the invention, therapeutic compositions are provided in non-capsular formulations such as microspheres (ranging from nanometers to micrometers in size), pastes, threads of various size, films and sprays.

Within certain aspects of the present invention, the therapeutic composition should be biocompatible, and release one or more therapeutic agents over a 15 period of several hours, days, or, months. For example, "quick release" or "burst" therapeutic compositions are provided that release greater than 10%, 20%, or 25% (w/v) of a therapeutic agent over a period of 7 to 10 days. Such "quick release" compositions should, within certain embodiments, be capable of releasing chemotherapeutic levels (where applicable) of a desired agent. Within other embodiments, "slow release" 20 therapeutic compositions are provided that release less than 1% (w/v) of a therapeutic agent over a period of 7 to 10 days. Further, therapeutic compositions of the present invention should preferably be stable for several months and capable of being produced and maintained under sterile conditions.

Within certain aspects of the present invention, therapeutic compositions 25 may be fashioned in any size ranging from 50 nm to 500 µm, depending upon the particular use. Alternatively, such compositions may also be readily applied as a "spray", which solidifies into a film or coating. Such sprays may be prepared from microspheres of a wide array of sizes, including for example, from 0.1 µm to 3 µm, from 10 µm to 30 µm, and from 30 µm to 100 µm.

30 Therapeutic compositions of the present invention may also be prepared in a variety of "paste" or gel forms. For example, within one embodiment of the

invention, therapeutic compositions are provided which are liquid at one temperature (e.g., temperature greater than 37°C, such as 40°C, 45°C, 50°C, 55°C or 60°C), and solid or semi-solid at another temperature (e.g., ambient body temperature, or any temperature lower than 37°C). Such "thermopastes" may be readily made utilizing a
5 variety of techniques (see, e.g., PCT Publication WO 98/24427). Other pastes may be applied as a liquid which solidify *in vivo* due to dissolution of a water-soluble component of the paste, and precipitation of encapsulated drug into the aqueous body environment.

Within yet other aspects of the invention, the therapeutic compositions
10 of the present invention may be formed as a film. Preferably, such films are generally less than 5, 4, 3, 2, or 1 mm thick, more preferably less than 0.75 mm, 0.5 mm, 0.25 mm, or, 0.10 mm thick. Films can also be generated of thicknesses less than 50 µm, 25 µm or 10 µm. Such films are preferably flexible with a good tensile strength (e.g., greater than 50, preferably greater than 100, and more preferably greater than 150 or
15 200 N/cm²), good adhesive properties (*i.e.*, adheres to moist or wet surfaces), and have controlled permeability.

Within certain embodiments of the invention, the therapeutic compositions may also comprise additional ingredients such as surfactants (e.g., Pluronics such as F-127, L-122, L-101, L-92, L-81, and L-61).

20 Within further aspects of the present invention, polymeric carriers are provided which are adapted to contain and release a hydrophobic compound, the carrier containing the hydrophobic compound in combination with a carbohydrate, protein or polypeptide. Within certain embodiments, the polymeric carrier contains or comprises regions, pockets, or granules of one or more hydrophobic compounds. For example,
25 within one embodiment of the invention, hydrophobic compounds may be incorporated within a matrix which contains the hydrophobic compound, followed by incorporation of the matrix within the polymeric carrier. A variety of matrices can be utilized in this regard, including for example, carbohydrates and polysaccharides such as starch, cellulose, dextran, methylcellulose, chitosan and hyaluronic acid, proteins or
30 polypeptides such as albumin, collagen and gelatin. Within alternative embodiments,

hydrophobic compounds may be contained within a hydrophobic core, and this core contained within a hydrophilic shell.

Other carriers that may likewise be utilized to contain and deliver the therapeutic agents described herein include: hydroxypropyl β cyclodextrin (Cserhati and Hollo, *Int. J. Pharm.* 108:69-75, 1994), liposomes (*see, e.g.*, Sharma et al., *Cancer Res.* 53:5877-5881, 1993; Sharma and Straubinger, *Pharm. Res.* 11(60):889-896, 1994; WO 93/18751; U.S. Patent No. 5,242,073), liposome/gel (WO 94/26254), nanocapsules (Bartoli et al., *J. Microencapsulation* 7(2):191-197, 1990), micelles (Alkan-Onyukşel et al., *Pharm. Res.* 11(2):206-212, 1994), implants (Jampel et al., *Invest. Ophthalm. Vis. Sci.* 34(11):3076-3083, 1993; Walter et al., *Cancer Res.* 54:22017-2212, 1994), nanoparticles (Violante and Lanzafame PAACR), nanoparticles - modified (U.S. Patent No. 5,145,684), nanoparticles (surface modified) (U.S. Patent No. 5,399,363), taxol emulsion/solution (U.S. Patent No. 5,407,683), micelle (surfactant) (U.S. Patent No. 5,403,858), synthetic phospholipid compounds (U.S. Patent No. 4,534,899), gas borne dispersion (U.S. Patent No. 5,301,664), liquid emulsions, foam, spray, gel, lotion, cream, ointment, dispersed vesicles, particles or droplets solid- or liquid- aerosols, microemulsions (U.S. Patent No. 5,330,756), polymeric shell (nano- and micro- capsule) (U.S. Patent No. 5,439,686), taxoid-based compositions in a surface-active agent (U.S. Patent No. 5,438,072), emulsion (Tarr et al., *Pharm Res.* 4: 62-165, 1987), nanospheres (Hagan et al., *Proc. Intern. Symp. Control Rel. Bioact. Mater.* 22, 1995; Kwon et al., *Pharm Res.* 12(2):192-195; Kwon et al., *Pharm Res.* 10(7):970-974; Yokoyama et al., *J. Contr. Rel.* 32:269-277, 1994; Gref et al., *Science* 263:1600-1603, 1994; Bazile et al., *J. Pharm. Sci.* 84:493-498, 1994) and implants (U.S. Patent No. 4,882,168).

Within further aspects of the invention, the stent graft which induces *in vivo* adhesion and/or an *in vivo* fibrotic reaction with vessel walls is further coated with a compound or compositions which delays the release of and/or activity of the adhesion causing or fibrosis inducing agent. Representative examples of such agents include biologically inert materials such as gelatin, PLGA/MePEG film, PLA, or polyethylene glycol, as well as biologically active materials such as heparin (e.g., to induce coagulation).

For example, in one embodiment of the invention the active agent of the stent graft (e.g., poly-l-lysine, fibronectin, or chitosan) is coated with a physical barrier. Such barriers can include inert biodegradable materials such as gelatin, PLGA/MePEG film, PLA, or polyethylene glycol among others. In the case of PLGA/ MePEG, once 5 the PLGA/ MePEG becomes exposed to blood, the MePEG will dissolve out of the PLGA, leaving channels through the PLGA to underlying layer of biologically active substance (e.g. poly-l-lysine, fibronectin, or chitosan) which then can initiate its biological activity.

Protection of a biologically active surface can also be accomplished by 10 coating the surface with an inert molecule that prevents access to the active site through steric hindrance, or by coating the surface with an inactive form of the biologically active substance, which is later activated. For example, the stent graft can be coated with an enzyme which causes either release of the biologically active agent, or activates the biologically active agent, or cleaves a non-active coating to expose the active agent.

15 For example, within one embodiment a stent graft is coated with a biologically active substance, such as poly-l-lysine in the usual manner. The stent graft is then further coated with a polymer (such as polyethylene glycol methyl ether, amino terminated to bind some of the active sites on the poly-l-lysine molecule using a cleavable cross-linking agent such as, for example, dithiobis(succinimidyl propionate) 20 or any other similar agent, e.g., dtbp, dtme, dtssp, (available from Pierce, Rockford, Illinois, USA) which creates a protective agent around the active sites. The stent graft may then be further coated with a mixture of dithiothreitol, B- mercaptoethanol, sodium borohydride (examples of S – S cleaving agents) in a slow release polymer. Once the stent graft is fully deployed, excluding the aneurysm, the slow release polymer will 25 release the cleaving agent, remove the protective polymer and expose the active agent.

Another example of a suitable surface coating is heparin which can be 30 coated on top of the biologically active agent (e.g. poly l lysine, fibronectin, or chitosan). The presence of heparin delays coagulation. As the heparin or other anticoagulant dissolved away, the anticoagulant activity would stop, and the newly exposed biologically active agent (e.g. poly l lysine, fibronectin, or chitosan) could initiate its intended action.

In another strategy, the stent graft can be coated with an inactive form of the biologically active coating, which is then activated once the stent graft is deployed. Such activation could be achieved by injecting another material into the aneurysm sac after the stent graft is deployed. In this iteration, the graft material could be coated with
5 an inactive form of the biologically active substance, such as poly l lysine, fibronectin, or chitosan, applied in the usual manner. Prior to the deployment of the aortic segment of the device, a catheter would be placed within the aneurysm sac via the opposite iliac artery, via an upper limb vessel such as a brachial artery, or via the same vessel as the aortic segment is inserted through so that once the stent graft is deployed, this catheter
10 will be inside the aneurysm sac, but outside the stent graft. The stent graft would then be deployed in the usual manner. Once the stent graft is fully deployed, excluding the aneurysm, the activating substance is injected into the aneurysm sac around the outside of the stent graft.

One example of this method would be coating the graft material with the
15 biologically active substance, such as poly-l-lysine, fibronectin, or chitosan, in the usual manner. The biologically active coating would then be covered with polyethylene glycol and these 2 substances would then be bonded through an ester bond using a condensation reaction. Prior to the deployment of the aortic segment of the device, a catheter would be placed within the aneurysm sac via the opposite iliac artery, via an
20 upper limb vessel such as a brachial artery, or via the same vessel as the aortic segment is inserted through. Once the stent graft is fully deployed, excluding the aneurysm, an esterase is injected into the aneurysm sac around the outside of the stent graft, which will cleave the bond between the ester and the biologically active substance, allowing the substance to initiate the desired reaction.

25 In further embodiments, it may be desirable to induce a blood vessel wall reaction or adhesion at each end of the stent graft, but in the central portion induce another reaction, e.g., a "filler effect" to tighten the seal between the stent graft and the blood vessel wall, thus filling the excluded aneurysm, or coagulating blood within the aneurysm sac. This might be done by placing these substances along the entire length
30 of the device, or by coating the ends of the device with an adhesive / fibrosis inducing agent, and the center portion with a combination of that agent, and a space occupying

agent such as, for example "Water Lock" (G - 400, Grain Processing Corporation, Muscatine, IA). The space occupying agent can then be covered with a layer of PLGA/ MePEG. Once the PLGA/ MePEG becomes exposed to blood, the MePEG will dissolve out of the PLGA, leaving channels through the PLGA to underlying layer of 5 swelling material, which then swell considerably, impinging upon the lumen of the aneurysm. Other materials which might be used include hyaluronic acid, chitosan particles in nonaqueous media such as propylene glycol.

Methods for Utilizing Stent Grafts

Stent grafts of the present invention may be utilized to induce a perigraft 10 reaction or to otherwise create a tight adhesive bond between an endovascular prosthesis and the vascular wall. Such grafts provide a solution to the following common problems associated with endovascular stent graft technology.

1. *Persistent Perigraft Leaks* – a formation of fibrotic response or adhesion or tight adhesive bond between the proximal and distal interfaces between the 15 stented portion of the stent graft and the vessel wall results in a more efficacious sealing around the device, and prevents late perigraft leaks arising at either end of the device even with a change in aneurysm morphology. Moreover, formation of a fibrous response or tight adhesion between the body of the graft and the aneurysm itself may result in occlusion of, or prevention of a perigraft leak due to retrograde flow (*i.e.*, 20 persistence of, or late reopening of the inferior mesenteric artery or lumbar arteries extending into the aneurysm). In addition, the coatings will induce or enhance blood clotting within the excluded aneurysm sac, which will further diminish the perigraft leak rate.

2. *Size of the Delivery Device* – one difficulty with present delivery 25 devices is that they are quite large due to the required thickness of the stent graft. By inducing a reaction in the wall, which in itself conveys strength to the graft portion of the stent graft prosthesis, a thinner graft material might be utilized.

3. *Anatomic Factors which limit Patients with Aneurysmal Disease who are Candidates for Treatment with Endovascular Stent Grafts* – by inducing a 30 fibrotic reaction or creating a tight durable adhesive bond between the prosthesis and

the vascular wall at the proximal and distal margins of the grafted portion of the prosthesis, the length of the neck, particularly the proximal neck, can be shorter than the present suggested 1.5 centimeters as the fibrotic reaction or tight adhesion between graft and vessel wall will enhance sealing of the graft even when there is a short length of

5 contact between the graft and vessel wall. (In an aneurysm, the walls are obviously dilated and thus extend away from the graft. When there is a long neck, apposition between graft material and vessel wall is only between the portion of vessel wall of "normal" diameter). In some cases, the portion of the vessel to which the device is to be anchored is dilated, e.g., a dilated iliac artery distal to an abdominal aortic aneurysm.

10 If this segment of the vessel is too dilated, it tends to continue expansion after graft insertion, resulting in late perigraft leaks. Patients with dilated iliac arteries or aortic neck might be denied therapy with uncoated devices. Creation of a firm bond between the graft and the vessel wall will prevent the neck from expanding further.

4. *Stent Graft Migration* – as the stent graft is firmly fixed against
15 the vessel wall by more than just hooks or force of expansion between the stent graft and the vessel wall, migration of the stent graft or portions of the stent graft is prevented.

5. *Expansion of Applications of Stent Grafts* – Present applications of stent grafts for practical purposes are limited to situations where the stent graft is
20 wholly deployed within a blood vessel. By strengthening the seal between the blood vessel wall and the device, this expands the possibility that the device can be used as an extravascular or even extra-anatomic conduit such as, but not limited to, between arteries, between an artery and a vein, or between veins, or between a vein and the peritoneal cavity. The expansion of stent grafts for these purposes is limited at least
25 partially by the risk of leak of bodily fluid such as blood because of poor sealing at the site where the stent graft enters or leaves a body tube such as a blood vessel) or cavity.

Thus, stent grafts, which are adapted to adhere to vessel walls, can be utilized in a wide variety of therapeutic applications. For example, a stent graft can be utilized to connect one artery to another, either intra-anatomically (e.g., to bypass
30 aneurysms (e.g., carotid artery, thoracic aorta, abdominal aorta, subclavian artery, iliac artery, coronary artery, venous); to treat dissections (e.g., carotid artery, coronary

artery, iliac artery, subclavian artery); to bypass long segment disease (e.g., carotid artery, coronary artery, aorta, iliac artery, femoral artery, popliteal artery), or to treat local rupture (e.g., carotid artery, aorta, iliac artery, renal artery, femoral artery). Stent grafts might also be utilized extra-anatomically, for example, for arterial to arterial or 5 arterial to venous dialysis fistula; or venous to venous for vascular access.

Stent grafts of the present invention may also be utilized to connect an artery to a vein (e.g., a dialysis fistula), or one vein to another (e.g., a portacaval shunt, or venous bypass).

A. Abdominal Aortic Aneurysms

In one representative example, stent grafts may be inserted into an 10 Abdominal Aorta Aneurysm (AAA), in order to treat or prevent rupture of the abdominal aorta. Briefly, using sterile conditions, under appropriate anesthesia and analgesia, the common femoral artery is surgically exposed and an arteriotomy is performed after clamping of the artery. A guide wire is manipulated through the iliac 15 arterial system and over this a catheter is inserted into the proximal abdominal aorta and an angiogram or intravascular ultrasound is performed. Subsequently the diagnostic catheter is exchanged over a guide wire for a delivery system, usually a sheath, containing the aortic portion of the stent graft system. If the device is an articulated bifurcated system, the most common iteration, than the ipsilateral iliac portion of the 20 prosthesis is connected to the aortic portion. The device is deployed by releasing it from its constrained configuration in the case of a stent graft composed of self-expanding stents. If the stent graft skeleton is composed of balloon expandable stents, it is released by withdrawal of the sheath and inflating a balloon to expand the stent graft in place. After release of the aortic and ipsilateral iliac portion of the prosthesis, 25 surgical exposure and cut down of the opposite iliac artery is performed and a guide wire is manipulated so that it passes through the deployed portion of the prosthesis. A similar delivery device containing the contralateral iliac limb of the prosthesis is then manipulated into the deployed aortic portion of the prosthesis and under fluoroscopic guidance is released in an appropriate position. The position is chosen so that the entire 30 grafted portion of the stent graft sits below the renal arteries and preferably is deployed

above the internal iliac arteries although one or both may be occluded. Depending on the patient's anatomy, further limb extensions may be inserted on either side. If the device is a tube graft, or a one piece bifurcated device, insertion via only one femoral artery may be required. A final angiogram is normally obtained by an angiographic 5 catheter position with its distal portion in the upper abdominal aorta.

B. Thoracic Aortic Aneurysm or Dissection

In another representative example, a stent graft may be utilized to treat or prevent a thoracic aortic aneurysm. Briefly, under appropriate anesthesia and analgesia, using sterile technique, a catheter is inserted via the right brachial artery into the 10 ascending thoracic aorta and an angiogram performed. Once the proximal and distal boundaries of the diseased segment of the aorta to be treated are defined, an operative exposure of one of the common femoral arteries, usually the right, and an operative arteriotomy is performed. A guide wire is manipulated through the diseased segment of the aorta and over this, the delivery device, usually a sheath, is advanced so that the 15 device is positioned across the diseased segment with the grafted portion of the stent immediately below the origin of the left subclavian artery. After contrast is injected to define the precise position of the stent graft, the device is deployed usually by withdrawing an outer sheath in the case of self-expanding stents so that the device is positioned immediately distal to the left subclavian artery and with its distal portion 20 extending beyond the diseased portion of the thoracic aorta but above the celiac axis. A final angiogram is performed via the catheter inserted by the right brachial artery. The vascular access wounds are then closed.

C. Delay of onset of activity of the stent coating

The time it takes to insert the device can be very long; for instance it 25 theoretically could be hours between the time that the first part of a device (usually the aortic segment) is deployed and the second part of the device is deployed. It is not until all the parts of the device are inserted that an adequate exclusion of the aneurysm is achieved. In other words, the coating on the device may cause blood clots to form on or around the device. Because blood is rushing around as well as through the device until

it is fully deployed, thereby excluding the aneurysm, such blood clots could be dislodged and washed downstream, or, might propagate distally. This could result in the inadvertent and undesirable occlusion or partial occlusion of blood vessels downstream from the intended site of insertion of the device, which the operator had
5 intended to keep open. Several strategies may be employed to address such difficulties.

For example, as discussed in more detail above, stent grafts may be constructed which are designed to delay the onset of activity of the adhesion inducing, and/or fibrosis forming agent (e.g., by coating the stent graft with a material such as heparin or PLGA which delays adhesion or fibrosis). Alternatively, stent grafts may be
10 constructed which are initially inert (i.e., do not substantially induce fibrosis or adhesion), and which are subsequently activated by another agent either at the time of insertion, or, more preferably, subsequent to insertion.

The following examples are offered by way of illustration, and not by
15 way of limitation.

EXAMPLES

EXAMPLE 1

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH FIBRONECTIN.

The coating apparatus consisted of an overhead stirrer (Fisher Scientific) orientated horizontally. A conical stainless steel head was attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft was pulled up onto the conical head until held firmly. The other end was attached to a clip-swivel device that held the graft in a horizontal position, but allowed the graft to rotate along its axis. The stirrer was then set to rotate at 30 rpm so that the whole graft rotated along the horizontal axis at this speed. A 1% (w/w) fibronectin (Calbiochem, San Diego, CA) solution in sterile water was prepared. Two hundred microlitres of this solution was slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotated. The fibronectin was then dried under a stream of nitrogen as the graft continued to rotate. When dry, the
30 graft was removed, turned around and the other end of the graft coated in the same

manner. Using this method a flexible ring of fibronectin was deposited on both ends of the graft without compromise of the physical characteristics of the graft.

EXAMPLE 2

5 COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH POLY-L-LYSINE.

The coating apparatus consisted of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head was attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft was pulled up onto the conical head until held firmly. The other end was attached to a clip-swivel device that held the graft 10 in a horizontal position, but allowed the graft to rotate along its axis. The stirrer was set to rotate at 30 rpm so that the whole graft rotated along the horizontal axis at this speed. A 1% (w/w) poly-L-Lysine (Sigma, St. Louis, MO) solution in sterile water was prepared. Two hundred microlitres of this solution was slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period 15 of 2 minutes as the graft rotated. The poly-L-Lysine was then dried under a stream of nitrogen as the graft continued to rotate. When dry, the graft was removed, turned around and the other end of the graft coated in the same manner. Using this method a flexible ring of poly-L-Lysine was deposited on both ends of the graft without compromise of the physical characteristics of the graft.

20

EXAMPLE 3

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH N-CARBOXYBUTYL CHITOSAN.

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head 25 until held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 1% (w/w) n-carboxybutyl chitosan (Carbomer, Westborough, MA) solution in sterile 30 water is prepared. Two hundred microlitres of this solution is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head

over a period of 2 minutes as the graft rotates. The n-carboxybutyl chitosan is dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end coated in the same manner. Using this method a flexible ring of n-carboxybutyl chitosan is deposited on both ends of the graft
5 without compromise of the physical characteristics of the graft.

EXAMPLE 4

COATING OF ANATOMIC AORTIC GRAFTS WITH BROMOCRIPTINE IN POLY(ETHYLENE VINYL ACETATE).

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A
10 4.5% w/w solution of EVA (60/40 ratio ethylene to vinyl acetate) (Polysciences USA) is prepared in dichloromethane. Bromocriptine mesylate (Sigma, St. Louis, MO) is dissolved/suspended in this solution at 5 mg/ml. Two hundred microlitres of this solution is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The
15 EVA/bromocriptine is dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end of the graft coated in the same manner. Using this method a flexible ring of EVA/bromocriptine is deposited on both ends of the graft without compromise of the physical characteristics of the graft.
20

25

EXAMPLE 5

PREPARATION OF INFLAMMATORY MICROCRYSTALS (MONOSODIUM URATE MONOHYDRATE AND CALCIUM PYROPHOSPHATE DIHYDRATE).

Monosodium urate monohydrate (MSUM) microcrystals were grown. A
30 solution of uric acid (certified A.C.S., Fisher Scientific) and sodium hydroxide at 55°C and pH 8.9 was left to stand overnight at room temperature. The crystals were rinsed

several times with cold (4°C) distilled water and dried at 60°C for 12 hours in a circulating hot-air oven (Fisher, Isotemp).

Triclinic calcium pyrophosphate dihydrate (CPPD) crystals were prepared as follows. A 250 ml beaker containing 103 ml distilled water was heated in a 5 water bath to 60 ± 2°C, and stirred constantly with a Teflon-coated stir bar. The stirring was slowed and 0.71 ml of concentrated hydrochloric acid and 0.32 ml of glacial acetic acid were added, followed by 0.6 g of calcium acetate (Fisher Certified Reagent). A 150 ml beaker containing 20 ml distilled water was heated to 60°C in the water bath, and 0.6 g calcium acetate added. The rate of stir was increased in the 250 ml beaker, 10 and 2 g of calcium acid pyrophosphate added rapidly. When the CaH₂P₂O₇ had nearly all dissolved, the rate of stirring was reduced for 5 minutes, then over a period of 15 seconds, the contents of the small beaker were poured into the large beaker with vigorous stirring. In the preparation of subsequent batches, a minute amount of triclinic CPPD crystals was added to the large beaker as seed material. Stirring was 15 discontinued, leaving a white gel. This was allowed to remain undisturbed in the cooling water bath. The pH of the supernatant was always less than 3.0. The gel collapsed as CPPD crystals formed in 24 hours. The crystals were washed in distilled water 3 times, washed in ethanol then acetone, and air dried.

20

EXAMPLE 6

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH INFLAMMATORY MICROCRYSTALS (MONOSODIUM URATE MONOHYDRATE OR CALCIUM PYROPHOSPHATE DIHYDRATE).

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the 25 stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until it is held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 4.5% w/w-solution of EVA (60/40 ratio ethylene to vinyl acetate) 30 (Polysciences USA) is prepared in dichloromethane. Inflammatory microcrystals (MSUM or CPPD) are ground in a pestle and mortar to a particle size of 10 to 50

micrometers and suspended in the solution at 5 mg/ml. Two hundred microlitres of this suspension is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The EVA/microcrystals is then dried under a stream of nitrogen as the graft continues to
5 rotate. When dry, the graft is removed, turned around and the other end of the graft coated in the same manner. Using this method a flexible ring of EVA/microcrystals is deposited on both ends of the graft without compromise of the physical characteristics of the graft.

10

EXAMPLE 7

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH INFLAMMATORY MICROCRYSTALS (MONOSODIUM URATE MONOHYDRATE OR CALCIUM PYROPHOSPHATE DIHYDRATE).

A 1% w/w solution of Polyurethane (PU) (Medical grade, Thermomedics, Woburn, MA) is prepared in dichloromethane. Inflammatory
15 microcrystals are ground in a pestle and mortar to a particle size of 10 to 50 micrometers and suspended in the solution at 2 mg/ml. Immediately prior to surgical insertion each end of the graft is inserted into the shaken suspension to a depth of approximately 5 mm for 2 seconds. The graft is air-dried (gently rotated by hand for 3 minutes). Using this method a flexible ring of EVA/microcrystals is deposited on both
20 ends of the graft without compromise of the physical characteristics of the graft.

EXAMPLE 8

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH BROMOCRIPTINE IN POLYURETHANE.

A 1% w/w solution of Polyurethane (PU) (Medical grade,
25 Thermomedics, Woburn, MA) is prepared in dichloromethane. Bromocriptine mesylate (Sigma, St. Louis, MO) at 5% w/w to PU is dissolved/suspended in this solution. The solution is placed in a 5 ml Fisher TLC atomizer (Fisher Scientific). Prior to surgery the graft is suspended vertically in a fume hood and 1 ml of the solution sprayed (using nitrogen propellant) onto the bottom 1 cm of the graft by revolving the graft through
30 360 degrees. The graft is dried for 2 minutes and then the other end of the graft is sprayed in a similar manner. The graft is then further air dried (gently rotated by hand

for 3 minutes). Using this method a flexible ring of bromocriptine/PU is deposited on both ends of the graft without compromise of the physical characteristics of the graft. It is envisaged that ultimately a bromocriptine/PU solution in DCM would be available to the surgeon in the form of a small aerosol can for the above procedure.

5

EXAMPLE 9

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH INFLAMMATORY MICROCRYSTALS (MONOSODIUM URATE MONOHYDRATE OR CALCIUM PYROPHOSPHATE DIHYDRATE).

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until it is held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 4.5% w/w solution of Poly (lactide co-glycolide) (85:15) (IV 0.61) (Birmingham Polymers, Birmingham, AL) blended with methoxypolyethylene glycol 350 (MePEG 350) (Union Carbide, Danbury, CT) in a ratio of 80:20 w/w (PLGA:MePEG) is prepared in dichloromethane. Inflammatory microcrystals are suspended in the solution at 5 mg/ml. Two hundred microlitres of this suspension is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The PLGA/MePEG/inflammatory crystals are then dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end of the graft coated in the same manner. Using this method a flexible ring of PLGA/MePEG/microcrystals is deposited on both ends of the graft without compromise of the physical characteristics of the graft.

EXAMPLE 10

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH SOLVENTS, SUCH AS ETHANOL OR CHLOROFORM.

A 1% w/w solution of Polyurethane (PU) (Medical grade, Thermomedics, Woburn, MA) is prepared in chloroform and stored until needed. Immediately prior to surgical insertion each end of the graft is dipped in the solution to a depth of approximately 5 mm for 2 seconds. The graft is immediately inserted into the animal before the polymer had fully dried. Using this method a flexible ring of PU containing significant amounts of chloroform is located at the required thrombogenic site without compromise of the physical characteristics of the graft. Alternatively, the PU can be dissolved at 1% (w/v) in a solution of chloroform: ethanol (80:20) to enable ethanol to be deposited at the site.

EXAMPLE 11

15 COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH ANGIOTENSIN 2
ENCAPSULATED IN POLYETHYLENE GLYCOL (PEG)

1.8 grams of Polyethylene glycol 1475 (Union Carbide, Danbury, CT) is placed in a flat-bottomed 20 ml glass scintillation vial and warmed to 50°C to melt the PEG in a water bath, 200 mg of glycerol (Fisher Scientific) is added. 2 mg of angiotensin 2 (Sigma, St. Louis, MO) is weighed into the vial and blended/dissolved into the melted PEG at 50°C. The vial is angled at 10 degrees in a water bath by use of a clamp. Each end of the graft is rotated in the molten formulation, so that a ring of material is deposited on the bottom 5 mm of the exterior surface of the graft. The graft is then cooled and stored at 4°C until use. Alternatively, to enable dipping immediately prior to surgery the PEG/angiotensin mixture is stored at 4°C until use. Immediately prior to surgery, the vial of PEG/angiotensin is warmed to 50°C for 2 minutes to melt and the graft is coated as described above.

EXAMPLE 12

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH TRANSFORMING GROWTH FACTOR- β (TGF- β) IN CROSSLINKED HYALURONIC ACID.

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 1% solution of hyaluronic acid (HA) (Sodium salt, Sigma, St. Louis, MO) in water, containing 30% glycerol (w/w to HA) (Fisher Scientific) and 8 mM 1-ethyl-3-(3 dimethylaminopropyl) carbodiimide (EDAC) (Sigma, St. Louis, MO) is prepared by dissolution overnight. TGF- β (Calbiochem, San Diego, CA) is dissolved at 0.01 mg/ml in this solution. Two hundred microlitres of this solution is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The HA/glycerol/TGF- β solution is dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end coated in the same manner. Using this method a flexible ring of HA/glycerol/TGF- β is deposited on both ends of the graft without compromise of the physical characteristics of the graft.

EXAMPLE 13

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH FIBROBLAST GROWTH FACTOR (FGF) IN CROSSLINKED CHITOSAN.

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 1% solution of chitosan (Medical grade, Carbomer, Westborough, MA) in dilute acetic

acid (pH 5), containing 30% glycerol (w/w to chitosan) (Fisher Scientific) and 0.5% glutaraldehyde (Sigma, St. Louis, MO) is prepared by dissolution overnight. FGF (Calbiochem, San Diego, CA) is dissolved at 0.01 mg/ml in this solution. Two hundred microlitres of this solution is slowly pipetted as a 3 mm wide ring located 5 mm from
5 the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The chitosan/glycerol/FGF solution is dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end coated in the same manner. Using this method a flexible ring of chitosan/glycerol/FGF is deposited on both ends of the graft without compromise of the
10 physical characteristics of the graft.

EXAMPLE 14

SCREENING PROCEDURE FOR ASSESSMENT OF PERIGRAFT REACTION

Large domestic rabbits are placed under general anesthetic. Using
15 aseptic precautions, the infrarenal abdominal aorta is exposed and clamped at its superior and inferior aspects. A longitudinal arterial wall arteriotomy is performed and a 2 millimeter diameter, 1 centimeter long segment of PTFE graft is inserted within the aorta and the proximal and distal aspect of the graft is sewn so that the entire aortic blood flow is through the graft which is contained in the abdominal aorta in the manner
20 of open surgical abdominal aortic repair in humans (except that no aneurysm is present in this model). The aortotomy is then surgically closed and the abdominal wound closed and the animal recovered.

The animals are randomized to receive standard PTFE grafts or grafts of which the middle 1 cm is coated alone circumferentially with nothing, or with an agent
25 that induces a vessel wall reaction or adhesion between a stent graft and vessel wall alone or contained in a slow release, polymer such as polycaprolactone or polylactic acid.

The animals are sacrificed between 1 and 6 weeks post surgery, the aorta is removed en bloc and the area in relation to the graft is grossly examined for adhesive
30 reaction. Any difference in morphology or histology of the vessel wall from portions of

the artery which contain no graft, portion which contain graft without coating, and portion which contained graft with coating is noted.

EXAMPLE 15

5

ANIMAL ABDOMINAL AORTIC ANEURYSM MODEL

Pigs or sheep are placed under general anesthetic. Using aseptic precautions the abdominal aorta is exposed. The animal is heparinized and the aorta is cross clamped below the renal arteries and above the bifurcation. Collaterals are temporarily controlled with vessel loops or clips that are removed upon completion of 10 the procedure. A longitudinal aortotomy is created in the arterial aspect of the aorta, and an elliptical shaped patch of rectus sheath from the same animal is sutured into the aortotomy to create an aneurysm. The aortic clamps from the lumbar arteries and collaterals are removed and the abdomen closed. After 30 days, the animal is reanesthetized and the abdominal wall again opened. A cutdown is performed on the 15 iliac artery and through this, a stent graft is positioned across the infrarenal abdominal aorta aneurysm extending from normal infrarenal abdominal aorta above to normal infrarenal abdominal aorta below the surgically created aneurysm and the device is released in a conventional way.

Animals are randomized into groups of 5 receiving uncoated stent grafts, 20 stent graft containing slow release polymer alone, and stent graft containing a biologically active or irritative substance as determined by the previously mentioned screening exam. After closure of the arteriotomy and of the abdominal wound, the animal is allowed to recover. At 6 weeks and 3 months post stent graft insertion, the animal is sacrificed and the aorta removed en bloc. The infrarenal abdominal aorta is 25 examined for evidence of histologic reaction and perigraft leaking.

From the foregoing, it is appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We claim:

1. A stent graft, comprising an endoluminal stent and a graft, wherein said stent graft releases an agent which induces the *in vivo* adhesion of the stent graft to vessel walls.
2. A stent graft, comprising an endoluminal stent and a graft, wherein said stent graft induces or accelerates an *in vivo* fibrotic reaction causing said stent graft to adhere to vessel walls.
3. The stent graft according to claim 1 or 2 wherein said stent graft releases a vessel wall irritant.
4. The stent graft according to claim 3 wherein said vessel wall irritant is selected from the group consisting of talcum powder, metallic beryllium, and silica.
5. The stent graft according to claim 1 or 2 wherein said stent graft releases a component of extracellular matrix.
6. The stent graft according to claim 1 wherein said agent is fibronectin.
7. The stent graft according to claim 1 or 2 wherein said stent graft releases polylysine, or, ethylenevinylacetate.
8. The stent graft according to claim 1 or 2 wherein said stent graft releases an inflammatory cytokine selected from the group consisting of TGF β , PDGF, VEGF, bFGF, TNF α , NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone.
9. The stent graft according to claim 1 wherein said agent is an adhesive.

10. The stent graft according to claim 9 wherein said adhesive is cyanoacrylate.
11. The stent graft according to claim 1 or 2 wherein said stent graft is bifurcated.
12. The stent graft according to claim 1 or 2 wherein said stent graft is a tube graft.
13. The stent graft according to claim 12 wherein said stent graft is cylindrical.
14. The stent graft according to claim 1 or 2 wherein said stent graft is self-expandable.
15. The stent graft according to claim 1 or 2 wherein said stent graft is balloon-expandable.
16. The stent graft according to claim 1 or 2 wherein the distal ends of said stent graft are adapted to release an agent which induces adhesion.
17. The stent graft according to claim 1 or 2 wherein the entire body of said stent graft is adapted to release an agent that induces adhesion.
18. The stent graft according to claim 1 or 2, further comprising a coating which delays the onset of adhesion or fibrosis.
19. The stent graft according to claim 1 wherein said agent is first activated from a previously inactive agent to an active agent.

20. The stent graft according to claim 1 wherein said stent graft is activated from a previously inactive stent graft to a stent graft that induces or accelerates an *in vivo* fibrotic reactions.

21. A method for treating patient having an aneurysm, comprising delivering to a patient a stent graft according to claim 1 or 2, such that risk of rupture of the aneurysm is reduced.

22. The method according to claim 21 wherein said aneurysm is an abdominal aortic aneurysm.

23. The method according to claim 21 wherein said aneurysm is a thoracic aortic aneurysm.

24. The method according to claim 21 wherein said aneurysm is an iliac aortic aneurysm.

25. A method for bypassing disease within a vessel, comprising delivering to a patient a stent graft according to any one of claims 1 to 20, such that vessel contents bypass said diseased portion of said vessel.

26. A method for creating communication between an artery and a vein, comprising delivering to a patient a stent graft according to any one of claims 1 to 20, such that a passageway is created between said artery and vein.

27. A method for creating communication between a first vein and a second vein, comprising delivering to a patient a stent graft according to any one of claims 1 to 20, such that a passageway is created between said first and second veins.

28. The method according to any one of claims 21, 25, 26, or, 27 wherein said stent graft is delivered into a patient in a constrained form, and self-expands into place after release of a constraining device.

29. The method according to any one of claims 21, 25, 26, or, 27 wherein said stent graft is delivered to said patient by balloon catheter.

30. A method of manufacturing an adhesive stent graft, comprising coating a stent graft with an agent which induces adhesion of the stent graft to vessel walls.

31. The method according to claim 30 wherein said stent graft is coated by spraying, dipping, or wrapping said stent graft with said agent.

32. The method according to claim 30 wherein said agent further comprises a polymer.



33. The method according to claim 30 wherein said agent is a vessel wall irritant.

34. The method according to claim 30 wherein said agent is an inflammatory cytokine.

35. The method according to claim 30 wherein said agent is an inflammatory crystal.

36. The method according to claim 30 wherein said agent is bFGF.

1/1

*Fig. 1**Fig. 2*

INTERNATIONAL SEARCH REPORT

Inte	ional Application No
PCT/CA 99/01237	

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7	A61L31/10	A61L31/16
		A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61L A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 06792 A (SCIMED LIFE SYSTEMS INC) 15 April 1993 (1993-04-15) page 22, line 10 - line 32 page 23, line 1 - line 2	1-36
X	WO 91 17789 A (STACK RICHARD S ;CLARK HOWARD G III (US); WALKER WILLIAM F (US)) 28 November 1991 (1991-11-28) page 21, line 18 - line 34; example	1-36
X	WO 97 46590 A (GORE ENTERPRISE HOLDINGS INC) 11 December 1997 (1997-12-11) claims; examples 54-58	1,2,7
X	EP 0 850 651 A (SCHNEIDER USA INC) 1 July 1998 (1998-07-01) column 4, line 16 - line 41	1,2,5-8, 11-36
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
---	--

14 April 2000	26/04/2000
---------------	------------

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer
--	--------------------

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

Inte	onal Application No
PCT/CA 99/01237	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 383 928 A (SCOTT NEAL A ET AL) 24 January 1995 (1995-01-24) column 5, line 34 - line 54 —	1,2,5-8, 11-36
X	WO 94 13268 A (KAPLAN AARON V) 23 June 1994 (1994-06-23) page 12, line 19 - line 36 —	1,2,5-8, 11-36
X	WO 94 01483 A (COLLAGEN CORP) 20 January 1994 (1994-01-20) claims —	1,2,5-8, 11-36
X	WO 97 46268 A (COOK INC ;FISCHER FRANK J JR (US)) 11 December 1997 (1997-12-11) page 10, line 10 - line 31 page 11, line 1 - line 21 —	1,2,5-8
X	EP 0 623 354 A (MEDTRONIC INC) 9 November 1994 (1994-11-09) page 4, line 39 - line 42 —	1,2,5-8
X	EP 0 734 721 A (ADVANCED CARDIOVASCULAR SYSTEM) 2 October 1996 (1996-10-02) column 4, line 33 - line 58 —	1,2,5-8
X	US 5 725 568 A (HASTINGS ROGER N) 10 March 1998 (1998-03-10) column 2, line 30 column 3, line 1 - line 3 —	1,2,5-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No

PCT/CA 99/01237

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9306792 A	15-04-1993	US	5968092 A		19-10-1999
		US	5464450 A		07-11-1995
		US	5551954 A		03-09-1996
		US	5500013 A		19-03-1996
		US	5769883 A		23-06-1998
WO 9117789 A	28-11-1991	AU	653159 B		22-09-1994
		AU	8001891 A		10-12-1991
		EP	0528993 A		03-03-1993
		EP	0737453 A		16-10-1996
		JP	5509008 T		16-12-1993
		US	5527337 A		18-06-1996
WO 9746590 A	11-12-1997	US	5914182 A		22-06-1999
		US	5874165 A		23-02-1999
		AU	3229797 A		05-01-1998
		EP	0910584 A		28-04-1999
		US	5897955 A		27-04-1999
EP 0850651 A	01-07-1998	CA	2225096 A		20-06-1998
		JP	10192413 A		28-07-1998
		US	5980972 A		09-11-1999
US 5383928 A	24-01-1995	NONE			
WO 9413268 A	23-06-1994	US	5342348 A		30-08-1994
		AU	5616894 A		04-07-1994
WO 9401483 A	20-01-1994	US	5324775 A		28-06-1994
		US	5328955 A		12-07-1994
		US	5308889 A		03-05-1994
		US	5292802 A		08-03-1994
		AU	677789 B		08-05-1997
		AU	4662093 A		31-01-1994
		EP	0648239 A		19-04-1995
		JP	8502082 T		05-03-1996
		US	5510418 A		23-04-1996
		US	5470911 A		28-11-1995
		US	5476666 A		19-12-1995
		US	5510121 A		23-04-1996
		US	5565519 A		15-10-1996
		US	5413791 A		09-05-1995
		US	5475052 A		12-12-1995
		US	5446091 A		29-08-1995
		US	5527856 A		18-06-1996
		US	5614587 A		25-03-1997
		US	5550188 A		27-08-1996
		US	5643464 A		01-07-1997
		US	5936035 A		10-08-1999
		US	5800541 A		01-09-1998
		US	5786421 A		28-07-1998
		US	5744545 A		28-04-1998
WO 9746268 A	11-12-1997	AU	3294497 A		05-01-1998
		EP	0906129 A		07-04-1999
EP 0623354 A	09-11-1994	US	5464650 A		07-11-1995
		JP	8033718 A		06-02-1996

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/01237

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: -
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 21-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/01237

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0623354 A		US	5837008 A	17-11-1998
		US	5679400 A	21-10-1997
		US	5624411 A	29-04-1997
		US	5776184 A	07-07-1998
		US	5824048 A	20-10-1998
EP 0734721 A	02-10-1996	US	5605696 A	25-02-1997
		AU	4825696 A	10-10-1996
		CA	2172187 A	01-10-1996
		JP	8266637 A	15-10-1996
US 5725568 A	10-03-1998	NONE		

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 July 2000 (13.07.2000)

PCT

(10) International Publication Number
WO 00/40278 A1

(51) International Patent Classification⁷: **A61L 31/10, 31/16, A61F 2/06**

(21) International Application Number: **PCT/CA99/01237**

(22) International Filing Date:
30 December 1999 (30.12.1999)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/114,731 31 December 1998 (31.12.1998) US
60/116,726 20 January 1999 (20.01.1999) US

(71) Applicants (*for all designated States except US*): **ANGIOTECH PHARMACEUTICALS, INC.** [CA/CA]; 6660 Northwest Marine Drive, Vancouver, British Columbia V6T 1Z4 (CA). **UNIVERSITY OF BRITISH COLUMBIA** [CA/CA]; IRC 331-2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MACHAN, Lindsay, S.** [CA/CA]; 3670 Cameron Avenue, Vancouver, British Columbia V6R 1A2 (CA). **JACKSON, John, K.** [CA/CA]; 4001 West 33rd Avenue, Vancouver, British Columbia V6N 2H9 (CA). **HUNTER, William, L.** [CA/CA]; 525 Penticton Street North, Vancouver, British Columbia V5K 3L7 (CA).

(74) Agents: **NASSIF, Omar, A. et al.**; Gowling Lafleur Henderson LLP, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

(48) Date of publication of this corrected version:

23 August 2001

(15) Information about Correction:

see PCT Gazette No. 34/2001 of 23 August 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/40278 A1

(54) Title: STENT GRAFTS WITH BIOACTIVE COATINGS

(57) Abstract: Stent grafts are provided comprising an endoluminal stent and a graft, wherein the stent graft releases an agent which induces the *in vivo* adhesion of the stent graft to vessel walls, or, otherwise induces or accelerates an *in vivo* fibrotic reaction causing said stent graft to adhere to vessel wall. Also provided are methods for making and using such stent grafts.

STENT GRAFTS WITH BIOACTIVE COATINGS

TECHNICAL FIELD

The present invention relates generally to pharmaceutical compositions, methods and devices, and more specifically, to compositions and methods for preparing 5 stent grafts to make them more adherent to, or, more readily incorporated within a vessel wall.

BACKGROUND OF THE INVENTION

Stent grafts have been developed in order to not only simply hold open a passageway, but also to bridge across diseased vasculature from healthy vessel to 10 healthy vessel. The most common application of stent grafts is to bypass an abdominal aortic aneurysm (AAA). Briefly, a stent graft is inserted over a guide wire, from the femoral or iliac artery and deployed within the aneurysm, resulting in maintenance of blood flow from an aorta of acceptable (usually normal) caliber above to a portion of aorta or iliac artery(s) of acceptable (usually normal) caliber below the aneurysm. The 15 aneurysm sac is thus excluded. Blood within this excluded sac thromboses and the aneurysm thus has no flow within it, presumably reducing the pressure and thus its tendency to burst.

Presently available stent grafts however have a number of problems. For example, current stent grafts are prone to persistent leakage around the area of the stent 20 graft. Hence, pressure within the sac stays at or near arterial pressure and there is still a risk of rupture. There are 3 common types of perigraft leakage. The first type is direct leakage around the stent graft. This can be persistent from the time of insertion because of poor sealing between the stent graft and vessel wall, or can develop later because the seal is lost. In addition, this problem can develop due to changes in the position or 25 orientation of the stent graft in relation to the aneurysm as the aneurysm grows, shrinks, elongates or shortens with time after treatment. The second type of perigraft leak can occur because there are side arteries extending out the treated segment of blood vessel. Once the aneurysm is excluded by the device, flow can reverse within these blood vessels and continue to fill the aneurysm sac around the stent graft. The third type of

perigraft leak can occur because of disarticulation of the device (in the case of modular devices) or because of the development of holes within the graft material because continuous pulsation of the vessel causes the graft material to rub against a metallic stent tyne eventually causing graft failure. Disarticulation of the device can develop
5 due to changes in shape of the aneurysm as it grows, shrinks, elongates or shortens with time after treatment.

Stent grafts are also limited in their application to only selected patients with aneurysms. For example, endovascular stents are an advance in the treatment of AAA as they offer the avoidance of standard therapy, which is a major operation with a
10 significant morbidity, mortality, long hospital stays, and prolonged recovery time. However, endovascular technology is only applicable to certain patients with AAA because (a) lack of a suitable route of access via the blood vessels to the intended site of deployment which prevents insertion of the device and (b) anatomy.

More specifically, in order to exclude an aneurysm, the graft material
15 needs to be of a certain strength and durability or it will tear. Typically, this implies a Dacron or PTFE graft material of conventional "surgical" thickness as thickness is one parameter to convey strength to the material. The thickness in the graft portion of the device results in the need for delivery devices which can be up to 32 French (10.67mm diameter). This almost always requires surgical exposure of the insertion site, usually a
20 common femoral artery and limits the application of the technology as a larger delivery device is more difficult to manipulate through the iliac artery to the intended site of delivery. Even "low profile" devices which use thinner graft material still are of a sufficient size that a surgical exposure of the blood vessel through which the device is inserted is almost always required. If the iliac arteries or aorta are very tortuous,
25 (frequently the case in AAA), or heavily calcified and diseased (another frequent association with AAA), this may be a contraindication to treatment or cause of failure of attempted treatment because of inability to advance a device to the site of deployment or potential for iliac artery rupture.

Furthermore, a stent graft typically bridges a diseased artery (usually an
30 aneurysm) extending from a portion of artery of acceptable caliber above to acceptable caliber below. To achieve a long lasting seal the artery of acceptable caliber above

(“proximal neck”) should be at least 1.5 cm long without a major branch vessel arising from it, and the artery of acceptable caliber below (“distal neck”) should be at least 1.0 cm long without a major branch vessel arising within that 1 cm. Shorter “necks” at either end of the diseased segment, necks which are sloping rather than cylindrical, or 5 necks which are smaller than the aneurysm but still dilated in comparison to the normal diameter for a vessel in this location predispose to failure of sealing around the stent graft or delayed perigraft leaks.

One further difficulty with present stent grafts is that over time certain devices have a tendency to migrate distally within the abdominal aorta. Such migration 10 results in device failure, perigraft leak and vessel occlusion.

Finally, there is long term uncertainty about the entire stent graft technology as a treatment for AAA. Standard open aneurysm repair is extremely durable. Uncertainties about endovascular stent grafts include whether they will lower the aneurysm rupture rate, rate of perigraft leak, device migration, ability to effectively 15 exclude aneurysms over a long term, and device rupture or disarticulation.

The present invention discloses novel compositions, methods for preparing, and devices related to stent grafts, and further provides other related advantages.

SUMMARY OF THE INVENTION

20 Briefly stated, the present invention provides stent grafts, compositions for coating stent grafts, as well as methods for making and using these grafts. Within one aspect of the invention stent grafts are provided which induce adhesion or fibrosis in vessel walls, thus increasing or accelerating adherence of the stent graft to the vessel wall. Within various embodiments, such adhesion or fibrosis is induced by release of 25 an agent from the stent graft.

Within related aspects of the present invention, stent grafts are provided comprising an endoluminal stent and a graft, wherein the stent graft releases an agent which induces the *in vivo* adhesion of the stent graft to vessel walls. As utilized herein, “induces adhesion to vessel walls” should be understood to refer to agents or 30 compositions which increase or accelerates a reaction between the stent graft and the

vessel wall, such that the position of the stent graft is fixed within the vessel. "Release of an agent" refers to any statistically significant presence of the agent, or a subcomponent thereof, which has disassociated from the stent graft.

Within a related aspect, stent grafts are provided comprising an endoluminal stent and a graft, wherein the stent graft induces or accelerates an *in vivo* fibrotic reaction causing the stent graft to adhere to vessel wall.

Within related aspects, stent grafts are constructed so that the graft itself is comprised of materials, which induce adhesion or fibrosis with vessel walls.

Within various embodiments of the invention, the stent graft is coated with a composition or compound, which delays the onset of adhesion or fibrosis. Representative examples of such agents include heparin, PLGA/MePEG, PLA, and polyethylene glycol. Within further embodiments the stent graft is activated prior to use (e.g., the agent is first activated from a previously inactive agent to an active agent, or, the stent graft is activated from a previously inactive stent graft to one that induces or accelerates an *in vivo* fibrotic reaction.). Such activation may be accomplished either before insertion, during insertion, or, subsequent to insertion.

Within one embodiment of the invention, the stent graft is adapted to release a vessel wall irritant. Representative examples of such irritants talcum powder, metallic beryllium, and silica. Other agents which may be released by the stent graft include components of extracellular matrix, fibronectin, polylysine, ethylenevinylacetate, and inflammatory cytokines such as TGF β , PDGF, VEGF, bFGF, TNF α , NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone, and adhesives such as cyanoacrylate.

A wide variety of stent grafts may be utilized within the context of the present invention, depending on the site and nature of treatment desired. Stent grafts may be, for example, bifurcated or tube grafts, cylindrical or tapered, self-expandable or balloon-expandable, unibody, or, modular. Moreover, the stent graft may be adapted to release the desired agent at only the distal ends, or along the entire body of the stent graft.

Also provided by the present invention are methods for treating patients having aneurysms (e.g., abdominal, thoracic, or iliac aortic aneurysms), for bypassing a

diseased portion of a vessel, or for creating communication or a passageway between one vessel and another (e.g., artery to vein or vice versa, or artery to artery or vein to vein), such that risk of rupture of the aneurysm is reduced. As utilized herein, it should be understood that 'reduction in the risk of rupture' or 'prevention of the risk of 5 rupture' refers to a statistically significant reduction in the, number, timing, or, rate of rupture, and not to a permanent prohibition of any rupture.

Within yet other aspects of the present invention methods are provided for manufacturing stent grafts, comprising the step of coating (e.g., spraying, dipping, or, wrapping) a stent graft with an agent which induces adhesion of the stent graft to 10 vessel walls (including for example, induction of an in vivo fibrotic reaction with vessel walls). Within related aspects, the stent graft can be constructed with materials, which release, or, by themselves induce adhesion or fibrosis with vessel walls.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, 15 various references are set forth herein which describe in more detail certain procedures or compositions, and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration of one representative stent graft. Dashed lines indicate coating of the graft with a desired agent at each end of the graft.

20 Figure 2 is a cross-sectional view of the stent graft illustrated in Figure 1.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

Prior to setting forth the invention, it may be helpful to an understanding thereof to first set forth definitions of certain terms that is used hereinafter.

25 "Stent graft" refers to devices comprising a graft or wrap (composed of a textile, polymer, or other suitable material such as biological tissue) which maintains the flow of fluids (e.g., blood) from one portion of a vessel to another, and an endovascular scaffolding or stent which holds open a body passageway and/or supports

the graft or wrap. The graft or wrap may be woven within a stent, contained within the lumen of a stent and/or exterior to a stent.

As discussed above, the present invention provides compositions, 5 methods and devices relating to stent grafts, which greatly increase the success and application of stent grafts. In particular, such stent grafts can accelerate or enhance occlusion of the lumen of the blood vessel outside the stent graft, and increase the strength and durability of the graft portion of the device.

Described in more detail below are methods for constructing stent 10 grafts, compositions and methods for generating stent grafts which adhere to a vessel wall, and methods for utilizing such stent grafts.

Construction of Stent Grafts

As noted above, stent grafts refers to devices comprising a graft or wrap which maintains the flow of fluids (e.g., blood) from one portion of a vessel to another, 15 or from one blood vessel to another, and an endovascular scaffolding or stent which holds open a body passageway and/or supports the graft or wrap. One representative stent graft is illustrated in Figures 1 and 2.

The graft portion of the stent may be composed of a textile, polymer, or other suitable material such as biological tissue. Representative examples of suitable 20 graft materials include textiles such as nylon, Orlon, Dacron, or woven Teflon, and non-textiles such as expanded polytetrafluoroethylene (PTFE). The graft or wrap may be woven within a stent, contained within the lumen of a stent and/or exterior to a stent.

The endovascular scaffolding or stent is adapted to hold open a body passageway and/or support the graft or wrap. Representative examples of stent grafts, 25 and methods for making and utilizing such grafts are described in more detail in U.S. Patent No. 5,810,870 entitled "Intraluminal Stent Graft"; U.S. Patent No. 5,776,180 entitled "Bifurcated Endoluminal Prosthesis"; U.S. Patent No. 5,755,774 entitled "Bistable Luminal Graft Endoprostheses"; U.S. Patent Nos. 5,735,892 and 5,700,285 entitled "Intraluminal Stent Graft"; U.S. Patent No. 5,723,004 entitled "Expandable 30 Supportive Endoluminal Grafts"; U.S. Patent No. 5,718,973 entitled "Tubular

Intraluminal Graft"; U.S. Patent No. 5,716,365 entitled "Bifurcated Endoluminal Prosthesis"; U.S. Patent No. 5,713,917 entitled "Apparatus and Method for Engrafting a Blood Vessel"; U.S. Patent No. 5,693,087 entitled "Method for Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,683,452 entitled "Method for
5 Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,683,448 entitled "Intraluminal Stent and Graft"; U.S. Patent No. 5,653,747 entitled "Luminal Graft Endoprostheses and Manufacture Thereof"; U.S. Patent No. 5,643,208 entitled "Balloon Device of Use in Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,639,278 entitled "Expandable Supportive Bifurcated Endoluminal Grafts"; U.S.
10 Patent No. 5,632,772 entitled "Expandable Supportive Branched Endoluminal Grafts"; U.S. Patent No. 5,628,788 entitled "Self-Expanding Endoluminal Stent-Graft"; U.S. Patent No. 5,591,229 entitled "Aortic Graft for Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,591,195 entitled "Apparatus and Methods for Engrafting a Blood Vessel"; U.S. Patent No. 5,578,072 entitled "Aortic Graft and Apparatus for
15 Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,578,071 entitled "Aortic Graft"; U.S. Patent No. 5,571,173 entitled "Graft to Repair a Body Passageway"; U.S. Patent No. 5,571,171 entitled "Method for Repairing an Artery in a Body"; U.S. Patent No. 5,522,880 entitled "Method for Repairing an Abdominal Aortic Aneurysm"; U.S. Patent No. 5,405,377 entitled "Intraluminal Stent"; and U.S. Patent No. 5,360,443
20 entitled "Aortic Graft for Repairing an Abdominal Aortic Aneurysm".

Compositions and Methods for Generating Stent Grafts
which Adhere to a Vessel Wall

Stent grafts of the present invention are coated with, or otherwise adapted to release an agent which induces adhesion to vessel walls. Stent grafts may be
25 adapted to release such an agent by (a) directly affixing to the implant or device a desired agent or composition (e.g., by either spraying the stent graft with a polymer/drug film, or by dipping the implant or device into a polymer/drug solution, or by other covalent or noncovalent means); (b) by coating the stent graft with a substance such as a hydrogel which will in turn absorb the desired agent or composition; (c) by
30 interweaving agent or composition coated thread into the stent graft (e.g., a polymer

which releases the agent formed into a thread) into the implant or device; (d) by inserting a sleeve or mesh which is comprised of or coated with the desired agent or composition; (e) constructing the stent graft itself with the desired agent or composition; or (f) otherwise impregnating the stent graft with the desired agent or composition. Suitable adhesion inducing agents may be readily determined based upon the animal models provided in Example 14 (Screening Procedure for Assessment of Perigraft Reaction) and Example 15 (Animal Abdominal Aortic Aneurysm Model).

Representative examples of adhesion inducing agents include irritants (e.g., talcum powder, metallic beryllium and silica), components of extracellular matrix (e.g., fibronectin); polymers (e.g., polylysine and ethylenevinylacetate); inflammatory cytokines (e.g., TGF β , PDGF, VEGF, bFGF, TNF α , NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone); and inflammatory microcrystals (e.g., crystalline minerals such as crystalline silicates). Other representative examples include Monocyte chemotactic protein, fibroblast stimulating factor 1, histamine, fibrin or fibrinogen, endothelin-1, angiotensin II, bovine collagen, bromocriptine, methylsergide, methotrexate, N-carboxybutyl chitosan, carbon tetrachloride, Thioacetamide, talcum powder, Metallic beryllium (or its oxides), Quartz dust, Polylysine, Fibrosin, and ethanol.

Optionally, within one embodiment of the invention a desired adhesion-inducing agent may be admixed with, blended with, conjugated to, or, otherwise modified to contain as a composition a polymer, which may be either biodegradable or non-biodegradable. Representative examples of biodegradable compositions include albumin, collagen, gelatin, hyaluronic acid, starch, cellulose (methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), casein, dextrans, polysaccharides, fibrinogen, poly(D,L-lactide), poly(D,L-lactide-co-glycolide), poly(glycolide), poly(hydroxybutyrate), poly(alkylcarbonate) and poly(orthoesters), polyesters, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene terephthalate), poly(malic acid), poly(tartronic acid), polyanhydrides, polyphosphazenes, poly(amino acids) and their copolymers (*see generally*, Illum, L., Davids, S.S. (eds.) "Polymers in Controlled Drug Delivery" Wright, Bristol, 1987;

Arshady, *J. Controlled Release* 17:1-22, 1991; Pitt, *Int. J. Phar.* 59:173-196, 1990; Holland et al., *J. Controlled Release* 4:155-0180, 1986). Representative examples of non-degradable polymers include poly(ethylene-vinyl acetate) ("EVA") copolymers, silicone rubber, acrylic polymers (polyacrylic acid, polymethylacrylic acid, 5 polymethylmethacrylate, polyalkylcynoacrylate), polyethylene, polypropylene, polyamides (nylon 6,6), polyurethane, poly(ester urethanes), poly(ether urethanes), poly(ester-urea), polyethers (poly(ethylene oxide), poly(propylene oxide), Pluronics and poly(tetramethylene glycol)), silicone rubbers and vinyl polymers (polyvinylpyrrolidone, poly(vinyl alcohol), poly(vinyl acetate phthalate). Polymers 10 may also be developed which are either anionic (e.g., alginate, carrageenan, carboxymethyl cellulose and poly(acrylic acid), or cationic (e.g., chitosan, poly-L-lysine, polyethylenimine, and poly(allyl amine)) (see generally, Dunn et al., *J. Applied Polymer Sci.* 50:353-365, 1993; Cascone et al., *J. Materials Sci.: Materials in Medicine* 5:770-774, 1994; Shiraishi et al., *Biol. Pharm. Bull.* 16(11):1164-1168, 1993; 15 Thacharodi and Rao, *Int'l J. Pharm.* 120:115-118, 1995; Miyazaki et al., *Int'l J. Pharm.* 118:257-263, 1995). Particularly preferred polymeric carriers include poly(ethylene-vinyl acetate), polyurethanes, poly (D,L-lactic acid) oligomers and polymers, poly (L-lactic acid) oligomers and polymers, poly (glycolic acid), copolymers of lactic acid and 20 glycolic acid, poly (caprolactone), poly (valerolactone), polyanhydrides, copolymers of poly (caprolactone) or poly (lactic acid) with a polyethylene glycol (e.g., MePEG), and blends, admixtures, or co-polymers of any of the above. Other preferred polymers include polysaccharides such as hyaluronic acid, chitosan and fucans, and copolymers 25 of polysaccharides with degradable polymers.

All of the above polymers may be blended or copolymerized in various 25 compositions as required.

Polymeric carriers can be fashioned in a variety of forms, with desired release characteristics and/or with specific desired properties. For example, polymeric carriers may be fashioned to release a therapeutic agent upon exposure to a specific triggering event such as pH (see, e.g., Heller et al., "Chemically Self-Regulated Drug 30 Delivery Systems," in *Polymers in Medicine III*, Elsevier Science Publishers B.V., Amsterdam, 1988, pp. 175-188; Kang et al., *J. Applied Polymer Sci.* 48:343-354, 1993;

Dong et al., *J. Controlled Release* 19:171-178, 1992; Dong and Hoffman, *J. Controlled Release* 15:141-152, 1991; Kim et al., *J. Controlled Release* 28:143-152, 1994; Cornejo-Bravo et al., *J. Controlled Release* 33:223-229, 1995; Wu and Lee, *Pharm. Res.* 10(10):1544-1547, 1993; Serres et al., *Pharm. Res.* 13(2):196-201, 1996; Peppas, 5 "Fundamentals of pH- and Temperature-Sensitive Delivery Systems," in Gurny et al. (eds.), *Pulsatile Drug Delivery*, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1993, pp. 41-55; Doelker, "Cellulose Derivatives," 1993, in Peppas and Langer (eds.), *Biopolymers I*, Springer-Verlag, Berlin). Representative examples of pH-sensitive polymers include poly(acrylic acid) and its derivatives (including for example, 10 homopolymers such as poly(aminocarboxylic acid); poly(acrylic acid); poly(methyl acrylic acid), copolymers of such homopolymers, and copolymers of poly(acrylic acid) and acrylmonomers such as those discussed above. Other pH sensitive polymers include polysaccharides such as cellulose acetate phthalate; hydroxypropylmethylcellulose phthalate; hydroxypropylmethylcellulose acetate 15 succinate; cellulose acetate trimellilate; and chitosan. Yet other pH sensitive polymers include any mixture of a pH sensitive polymer and a water-soluble polymer.

Likewise, polymeric carriers can be fashioned which are temperature sensitive (see, e.g., Chen et al., "Novel Hydrogels of a Temperature-Sensitive Pluronic Grafted to a Bioadhesive Polyacrylic Acid Backbone for Vaginal Drug Delivery," in 20 *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.* 22:167-168, Controlled Release Society, Inc., 1995; Okano, "Molecular Design of Stimuli-Responsive Hydrogels for Temporal Controlled Drug Delivery," in *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.* 22:111-112, Controlled Release Society, Inc., 1995; Johnston et al., *Pharm. Res.* 9(3):425-433, 1992; Tung, *Int'l J. Pharm.* 107:85-90, 1994; Harsh and Gehrke, *J. Controlled Release* 17:175-186, 1991; Bae et al., *Pharm. Res.* 8(4):531-537, 1991; 25 Dinarvand and D'Emanuele, *J. Controlled Release* 36:221-227, 1995; Yu and Grainger, "Novel Thermo-sensitive Amphiphilic Gels: Poly N-isopropylacrylamide-co-sodium acrylate-co-n-N-alkylacrylamide Network Synthesis and Physicochemical Characterization," Dept. of Chemical & Biological Sci., Oregon Graduate Institute of 30 Science & Technology, Beaverton, OR, pp. 820-821; Zhou and Smid, "Physical Hydrogels of Associative Star Polymers," Polymer Research Institute, Dept. of

Chemistry, College of Environmental Science and Forestry, State Univ. of New York, Syracuse, NY, pp. 822-823; Hoffman et al., "Characterizing Pore Sizes and Water 'Structure' in Stimuli-Responsive Hydrogels," Center for Bioengineering, Univ. of Washington, Seattle, WA, p. 828; Yu and Grainger, "Thermo-sensitive Swelling Behavior in Crosslinked N-isopropylacrylamide Networks: Cationic, Anionic and Ampholytic Hydrogels," Dept. of Chemical & Biological Sci., Oregon Graduate Institute of Science & Technology, Beaverton, OR, pp. 829-830; Kim et al., *Pharm. Res.* 9(3):283-290, 1992; Bae et al., *Pharm. Res.* 8(5):624-628, 1991; Kono et al., *J. Controlled Release* 30:69-75, 1994; Yoshida et al., *J. Controlled Release* 32:97-102, 1994; Okano et al., *J. Controlled Release* 36:125-133, 1995; Chun and Kim, *J. Controlled Release* 38:39-47, 1996; D'Emanuele and Dinarvand, *Int'l J. Pharm.* 118:237-242, 1995; Katono et al., *J. Controlled Release* 16:215-228, 1991; Hoffman, "Thermally Reversible Hydrogels Containing Biologically Active Species," in Migliaresi et al. (eds.), *Polymers in Medicine III*, Elsevier Science Publishers B.V., Amsterdam, 1988, pp. 161-167; Hoffman, "Applications of Thermally Reversible Polymers and Hydrogels in Therapeutics and Diagnostics," in *Third International Symposium on Recent Advances in Drug Delivery Systems*, Salt Lake City, UT, Feb. 24-27, 1987, pp. 297-305; Gutowska et al., *J. Controlled Release* 22:95-104, 1992; Palasis and Gehrke, *J. Controlled Release* 18:1-12, 1992; Paavola et al., *Pharm. Res.* 12(12):1997-2002, 1995).

Representative examples of thermogelling polymers, and their gelatin temperature (LCST (°C)) include homopolymers such as poly(N-methyl-N-n-propylacrylamide), 19.8; poly(N-n-propylacrylamide), 21.5; poly(N-methyl-N-isopropylacrylamide), 22.3; poly(N-n-propylmethacrylamide), 28.0; poly(N-isopropylacrylamide), 30.9; poly(N, n-diethylacrylamide), 32.0; poly(N-isopropylmethacrylamide), 44.0; poly(N-cyclopropylacrylamide), 45.5; poly(N-ethylmethacrylamide), 50.0; poly(N-methyl-N-ethylacrylamide), 56.0; poly(N-cyclopropylmethacrylamide), 59.0; poly(N-ethylacrylamide), 72.0. Moreover thermogelling polymers may be made by preparing copolymers between (among) monomers of the above, or by combining such homopolymers with other water-soluble polymers such as acrylmonomers (e.g., acrylic acid and derivatives thereof such as

methylacrylic acid, acrylate and derivatives thereof such as butyl methacrylate, acrylamide, and N-n-butyl acrylamide).

Other representative examples of thermogelling polymers include cellulose ether derivatives such as hydroxypropyl cellulose, 41°C; methyl cellulose, 5 55°C; hydroxypropylmethyl cellulose, 66°C; and ethylhydroxyethyl cellulose, and Pluronics such as F-127, 10 - 15°C; L-122, 19°C; L-92, 26°C; L-81,-20°C; and L-61, 24°C.

Therapeutic agents may be linked by occlusion in the matrices of the polymer, bound by covalent linkages, or encapsulated in microcapsules. Within certain 10 preferred embodiments of the invention, therapeutic compositions are provided in non-capsular formulations such as microspheres (ranging from nanometers to micrometers in size), pastes, threads of various size, films and sprays.

Within certain aspects of the present invention, the therapeutic composition should be biocompatible, and release one or more therapeutic agents over a 15 period of several hours, days, or, months. For example, "quick release" or "burst" therapeutic compositions are provided that release greater than 10%, 20%, or 25% (w/v) of a therapeutic agent over a period of 7 to 10 days. Such "quick release" compositions should, within certain embodiments, be capable of releasing chemotherapeutic levels (where applicable) of a desired agent. Within other embodiments, "slow release" 20 therapeutic compositions are provided that release less than 1% (w/v) of a therapeutic agent over a period of 7 to 10 days. Further, therapeutic compositions of the present invention should preferably be stable for several months and capable of being produced and maintained under sterile conditions.

Within certain aspects of the present invention, therapeutic compositions 25 may be fashioned in any size ranging from 50 nm to 500 µm, depending upon the particular use. Alternatively, such compositions may also be readily applied as a "spray", which solidifies into a film or coating. Such sprays may be prepared from microspheres of a wide array of sizes, including for example, from 0.1 µm to 3 µm, from 10 µm to 30 µm, and from 30 µm to 100 µm.

30 Therapeutic compositions of the present invention may also be prepared in a variety of "paste" or gel forms. For example, within one embodiment of the

invention, therapeutic compositions are provided which are liquid at one temperature (e.g., temperature greater than 37°C, such as 40°C, 45°C, 50°C, 55°C or 60°C), and solid or semi-solid at another temperature (e.g., ambient body temperature, or any temperature lower than 37°C). Such "thermopastes" may be readily made utilizing a
5 variety of techniques (see, e.g., PCT Publication WO 98/24427). Other pastes may be applied as a liquid which solidify *in vivo* due to dissolution of a water-soluble component of the paste, and precipitation of encapsulated drug into the aqueous body environment.

Within yet other aspects of the invention, the therapeutic compositions
10 of the present invention may be formed as a film. Preferably, such films are generally less than 5, 4, 3, 2, or 1 mm thick, more preferably less than 0.75 mm, 0.5 mm, 0.25 mm, or, 0.10 mm thick. Films can also be generated of thicknesses less than 50 µm, 25 µm or 10 µm. Such films are preferably flexible with a good tensile strength (e.g., greater than 50, preferably greater than 100, and more preferably greater than 150 or
15 200 N/cm²), good adhesive properties (*i.e.*, adheres to moist or wet surfaces), and have controlled permeability.

Within certain embodiments of the invention, the therapeutic compositions may also comprise additional ingredients such as surfactants (e.g., Pluronics such as F-127, L-122, L-101, L-92, L-81, and L-61).

Within further aspects of the present invention, polymeric carriers are provided which are adapted to contain and release a hydrophobic compound, the carrier containing the hydrophobic compound in combination with a carbohydrate, protein or polypeptide. Within certain embodiments, the polymeric carrier contains or comprises regions, pockets, or granules of one or more hydrophobic compounds. For example,
20 within one embodiment of the invention, hydrophobic compounds may be incorporated within a matrix which contains the hydrophobic compound, followed by incorporation of the matrix within the polymeric carrier. A variety of matrices can be utilized in this regard, including for example, carbohydrates and polysaccharides such as starch, cellulose, dextran, methylcellulose, chitosan and hyaluronic acid, proteins or
25 polypeptides such as albumin, collagen and gelatin. Within alternative embodiments,
30

hydrophobic compounds may be contained within a hydrophobic core, and this core contained within a hydrophilic shell.

Other carriers that may likewise be utilized to contain and deliver the therapeutic agents described herein include: hydroxypropyl β cyclodextrin (Cserhati and Hollo, *Int. J. Pharm.* 108:69-75, 1994), liposomes (*see, e.g.*, Sharma et al., *Cancer Res.* 53:5877-5881, 1993; Sharma and Straubinger, *Pharm. Res.* 11(60):889-896, 1994; WO 93/18751; U.S. Patent No. 5,242,073), liposome/gel (WO 94/26254), nanocapsules (Bartoli et al., *J. Microencapsulation* 7(2):191-197, 1990), micelles (Alkan-Onyuksel et al., *Pharm. Res.* 11(2):206-212, 1994), implants (Jampel et al., *Invest. Ophthalmol. Vis. Sci.* 34(11):3076-3083, 1993; Walter et al., *Cancer Res.* 54:22017-2212, 1994), nanoparticles (Violante and Lanzafame PAACR), nanoparticles - modified (U.S. Patent No. 5,145,684), nanoparticles (surface modified) (U.S. Patent No. 5,399,363), taxol emulsion/solution (U.S. Patent No. 5,407,683), micelle (surfactant) (U.S. Patent No. 5,403,858), synthetic phospholipid compounds (U.S. Patent No. 4,534,899), gas borne dispersion (U.S. Patent No. 5,301,664), liquid emulsions, foam, spray, gel, lotion, cream, ointment, dispersed vesicles, particles or droplets solid- or liquid- aerosols, microemulsions (U.S. Patent No. 5,330,756), polymeric shell (nano- and micro-capsule) (U.S. Patent No. 5,439,686), taxoid-based compositions in a surface-active agent (U.S. Patent No. 5,438,072), emulsion (Tarr et al., *Pharm Res.* 4: 62-165, 1987), nanospheres (Hagan et al., *Proc. Intern. Symp. Control Rel. Bioact. Mater.* 22, 1995; Kwon et al., *Pharm Res.* 12(2):192-195; Kwon et al., *Pharm Res.* 10(7):970-974; Yokoyama et al., *J. Contr. Rel.* 32:269-277, 1994; Gref et al., *Science* 263:1600-1603, 1994; Bazile et al., *J. Pharm. Sci.* 84:493-498, 1994) and implants (U.S. Patent No. 4,882,168).

Within further aspects of the invention, the stent graft which induces *in vivo* adhesion and/or an *in vivo* fibrotic reaction with vessel walls is further coated with a compound or compositions which delays the release of and/or activity of the adhesion causing or fibrosis inducing agent. Representative examples of such agents include biologically inert materials such as gelatin, PLGA/MePEG film, PLA, or polyethylene glycol, as well as biologically active materials such as heparin (e.g., to induce coagulation).

For example, in one embodiment of the invention the active agent of the stent graft (e.g., poly-l-lysine, fibronectin, or chitosan) is coated with a physical barrier. Such barriers can include inert biodegradable materials such as gelatin, PLGA/MePEG film, PLA, or polyethylene glycol among others. In the case of PLGA/ MePEG, once 5 the PLGA/ MePEG becomes exposed to blood, the MePEG will dissolve out of the PLGA, leaving channels through the PLGA to underlying layer of biologically active substance (e.g. poly-l-lysine, fibronectin, or chitosan) which then can initiate its biological activity.

Protection of a biologically active surface can also be accomplished by 10 coating the surface with an inert molecule that prevents access to the active site through steric hindrance, or by coating the surface with an inactive form of the biologically active substance, which is later activated. For example, the stent graft can be coated with an enzyme which causes either release of the biologically active agent, or activates the biologically active agent, or cleaves a non-active coating to expose the active agent.

15 For example, within one embodiment a stent graft is coated with a biologically active substance, such as poly-l-lysine in the usual manner. The stent graft is then further coated with a polymer (such as polyethylene glycol methyl ether, amino terminated to bind some of the active sites on the poly-l-lysine molecule using a cleavable cross-linking agent such as, for example, dithiobis(succinimidyl propionate) 20 or any other similar agent, e.g., dtbp, dtme, dtssp, (available from Pierce, Rockford, Illinois, USA) which creates a protective agent around the active sites. The stent graft may then be further coated with a mixture of dithiothreitol, B- mercaptoethanol, sodium borohydride (examples of S – S cleaving agents) in a slow release polymer. Once the stent graft is fully deployed, excluding the aneurysm, the slow release polymer will 25 release the cleaving agent, remove the protective polymer and expose the active agent.

Another example of a suitable surface coating is heparin which can be 30 coated on top of the biologically active agent (e.g. poly l lysine, fibronectin, or chitosan). The presence of heparin delays coagulation. As the heparin or other anticoagulant dissolved away, the anticoagulant activity would stop, and the newly exposed biologically active agent (e.g. poly l lysine, fibronectin, or chitosan) could initiate its intended action.

In another strategy, the stent graft can be coated with an inactive form of the biologically active coating, which is then activated once the stent graft is deployed. Such activation could be achieved by injecting another material into the aneurysm sac after the stent graft is deployed. In this iteration, the graft material could be coated with
5 an inactive form of the biologically active substance, such as poly l lysine, fibronectin, or chitosan, applied in the usual manner. Prior to the deployment of the aortic segment of the device, a catheter would be placed within the aneurysm sac via the opposite iliac artery, via an upper limb vessel such as a brachial artery, or via the same vessel as the aortic segment is inserted through so that once the stent graft is deployed, this catheter
10 will be inside the aneurysm sac, but outside the stent graft. The stent graft would then be deployed in the usual manner. Once the stent graft is fully deployed, excluding the aneurysm, the activating substance is injected into the aneurysm sac around the outside of the stent graft.

One example of this method would be coating the graft material with the
15 biologically active substance, such as poly-l-lysine, fibronectin, or chitosan, in the usual manner. The biologically active coating would then be covered with polyethylene glycol and these 2 substances would then be bonded through an ester bond using a condensation reaction. Prior to the deployment of the aortic segment of the device, a catheter would be placed within the aneurysm sac via the opposite iliac artery, via an
20 upper limb vessel such as a brachial artery, or via the same vessel as the aortic segment is inserted through. Once the stent graft is fully deployed, excluding the aneurysm, an esterase is injected into the aneurysm sac around the outside of the stent graft, which will cleave the bond between the ester and the biologically active substance, allowing the substance to initiate the desired reaction.

25 In further embodiments, it may be desirable to induce a blood vessel wall reaction or adhesion at each end of the stent graft, but in the central portion induce another reaction, e.g., a "filler effect" to tighten the seal between the stent graft and the blood vessel wall, thus filling the excluded aneurysm, or coagulating blood within the aneurysm sac. This might be done by placing these substances along the entire length
30 of the device, or by coating the ends of the device with an adhesive / fibrosis inducing agent, and the center portion with a combination of that agent, and a space occupying

agent such as, for example "Water Lock" (G - 400, Grain Processing Corporation, Muscatine, IA). The space occupying agent can then be covered with a layer of PLGA/ MePEG. Once the PLGA/ MePEG becomes exposed to blood, the MePEG will dissolve out of the PLGA, leaving channels through the PLGA to underlying layer of 5 swelling material, which then swell considerably, impinging upon the lumen of the aneurysm. Other materials which might be used include hyaluronic acid, chitosan particles in nonaqueous media such as propylene glycol.

Methods for Utilizing Stent Grafts

Stent grafts of the present invention may be utilized to induce a perigraft reaction or to otherwise create a tight adhesive bond between an endovascular prosthesis and the vascular wall. Such grafts provide a solution to the following common problems associated with endovascular stent graft technology.

1. *Persistent Perigraft Leaks* – a formation of fibrotic response or adhesion or tight adhesive bond between the proximal and distal interfaces between the 15 stented portion of the stent graft and the vessel wall results in a more efficacious sealing around the device, and prevents late perigraft leaks arising at either end of the device even with a change in aneurysm morphology. Moreover, formation of a fibrous response or tight adhesion between the body of the graft and the aneurysm itself may result in occlusion of, or prevention of a perigraft leak due to retrograde flow (*i.e.*, 20 persistence of, or late reopening of the inferior mesenteric artery or lumbar arteries extending into the aneurysm). In addition, the coatings will induce or enhance blood clotting within the excluded aneurysm sac, which will further diminish the perigraft leak rate.

2. *Size of the Delivery Device* – one difficulty with present delivery 25 devices is that they are quite large due to the required thickness of the stent graft. By inducing a reaction in the wall, which in itself conveys strength to the graft portion of the stent graft prosthesis, a thinner graft material might be utilized.

3. *Anatomic Factors which limit Patients with Aneurysmal Disease who are Candidates for Treatment with Endovascular Stent Grafts* – by inducing a 30 fibrotic reaction or creating a tight durable adhesive bond between the prosthesis and

- the vascular wall at the proximal and distal margins of the grafted portion of the prosthesis, the length of the neck, particularly the proximal neck, can be shorter than the present suggested 1.5 centimeters as the fibrotic reaction or tight adhesion between graft and vessel wall will enhance sealing of the graft even when there is a short length of
- 5 contact between the graft and vessel wall. (In an aneurysm, the walls are obviously dilated and thus extend away from the graft. When there is a long neck, apposition between graft material and vessel wall is only between the portion of vessel wall of "normal" diameter). In some cases, the portion of the vessel to which the device is to be anchored is dilated, e.g., a dilated iliac artery distal to an abdominal aortic aneurysm.
- 10 If this segment of the vessel is too dilated, it tends to continue expansion after graft insertion, resulting in late perigraft leaks. Patients with dilated iliac arteries or aortic neck might be denied therapy with uncoated devices. Creation of a firm bond between the graft and the vessel wall will prevent the neck from expanding further.

4. *Stent Graft Migration* – as the stent graft is firmly fixed against
- 15 the vessel wall by more than just hooks or force of expansion between the stent graft and the vessel wall, migration of the stent graft or portions of the stent graft is prevented.

5. *Expansion of Applications of Stent Grafts* – Present applications of stent grafts for practical purposes are limited to situations where the stent graft is
- 20 wholly deployed within a blood vessel. By strengthening the seal between the blood vessel wall and the device, this expands the possibility that the device can be used as an extravascular or even extra-anatomic conduit such as, but not limited to, between arteries, between an artery and a vein, or between veins, or between a vein and the peritoneal cavity. The expansion of stent grafts for these purposes is limited at least
- 25 partially by the risk of leak of bodily fluid such as blood because of poor sealing at the site where the stent graft enters or leaves a body tube such as a blood vessel) or cavity.

Thus, stent grafts, which are adapted to adhere to vessel walls, can be utilized in a wide variety of therapeutic applications. For example, a stent graft can be utilized to connect one artery to another, either intra-anatomically (e.g., to bypass

30 aneurysms (e.g., carotid artery, thoracic aorta, abdominal aorta, subclavian artery, iliac artery, coronary artery, venous); to treat dissections (e.g., carotid artery, coronary

artery, iliac artery, subclavian artery); to bypass long segment disease (e.g., carotid artery, coronary artery, aorta, iliac artery, femoral artery, popliteal artery), or to treat local rupture (e.g., carotid artery, aorta, iliac artery, renal artery, femoral artery). Stent grafts might also be utilized extra-anatomically, for example, for arterial to arterial or 5 arterial to venous dialysis fistula; or venous to venous for vascular access.

Stent grafts of the present invention may also be utilized to connect an artery to a vein (e.g., a dialysis fistula), or one vein to another (e.g., a portacaval shunt, or venous bypass).

A. Abdominal Aortic Aneurysms

In one representative example, stent grafts may be inserted into an 10 Abdominal Aorta Aneurysm (AAA), in order to treat or prevent rupture of the abdominal aorta. Briefly, using sterile conditions, under appropriate anesthesia and analgesia, the common femoral artery is surgically exposed and an arteriotomy is performed after clamping of the artery. A guide wire is manipulated through the iliac 15 arterial system and over this a catheter is inserted into the proximal abdominal aorta and an angiogram or intravascular ultrasound is performed. Subsequently the diagnostic catheter is exchanged over a guide wire for a delivery system, usually a sheath, containing the aortic portion of the stent graft system. If the device is an articulated bifurcated system, the most common iteration, than the ipsilateral iliac portion of the 20 prosthesis is connected to the aortic portion. The device is deployed by releasing it from its constrained configuration in the case of a stent graft composed of self-expanding stents. If the stent graft skeleton is composed of balloon expandable stents, it is released by withdrawal of the sheath and inflating a balloon to expand the stent 25 graft in place. After release of the aortic and ipsilateral iliac portion of the prosthesis, surgical exposure and cut down of the opposite iliac artery is performed and a guide wire is manipulated so that it passes through the deployed portion of the prosthesis. A similar delivery device containing the contralateral iliac limb of the prosthesis is then manipulated into the deployed aortic portion of the prosthesis and under fluoroscopic 30 guidance is released in an appropriate position. The position is chosen so that the entire grafted portion of the stent graft sits below the renal arteries and preferably is deployed

above the internal iliac arteries although one or both may be occluded. Depending on the patient's anatomy, further limb extensions may be inserted on either side. If the device is a tube graft, or a one piece bifurcated device, insertion via only one femoral artery may be required. A final angiogram is normally obtained by an angiographic catheter position with its distal portion in the upper abdominal aorta.

B. Thoracic Aortic Aneurysm or Dissection

In another representative example, a stent graft may be utilized to treat or prevent a thoracic aortic aneurysm. Briefly, under appropriate anesthesia and analgesia, using sterile technique, a catheter is inserted via the right brachial artery into the ascending thoracic aorta and an angiogram performed. Once the proximal and distal boundaries of the diseased segment of the aorta to be treated are defined, an operative exposure of one of the common femoral arteries, usually the right, and an operative arteriotomy is performed. A guide wire is manipulated through the diseased segment of the aorta and over this, the delivery device, usually a sheath, is advanced so that the device is positioned across the diseased segment with the grafted portion of the stent immediately below the origin of the left subclavian artery. After contrast is injected to define the precise position of the stent graft, the device is deployed usually by withdrawing an outer sheath in the case of self-expanding stents so that the device is positioned immediately distal to the left subclavian artery and with its distal portion extending beyond the diseased portion of the thoracic aorta but above the celiac axis. A final angiogram is performed via the catheter inserted by the right brachial artery. The vascular access wounds are then closed.

C. Delay of onset of activity of the stent coating

The time it takes to insert the device can be very long; for instance it theoretically could be hours between the time that the first part of a device (usually the aortic segment) is deployed and the second part of the device is deployed. It is not until all the parts of the device are inserted that an adequate exclusion of the aneurysm is achieved. In other words, the coating on the device may cause blood clots to form on or around the device. Because blood is rushing around as well as through the device until

it is fully deployed, thereby excluding the aneurysm, such blood clots could be dislodged and washed downstream, or, might propagate distally. This could result in the inadvertent and undesirable occlusion or partial occlusion of blood vessels downstream from the intended site of insertion of the device, which the operator had
5 intended to keep open. Several strategies may be employed to address such difficulties.

For example, as discussed in more detail above, stent grafts may be constructed which are designed to delay the onset of activity of the adhesion inducing, and/or fibrosis forming agent (e.g., by coating the stent graft with a material such as heparin or PLGA which delays adhesion or fibrosis). Alternatively, stent grafts may be
10 constructed which are initially inert (i.e., do not substantially induce fibrosis or adhesion), and which are subsequently activated by another agent either at the time of insertion, or, more preferably, subsequent to insertion.

The following examples are offered by way of illustration, and not by
15 way of limitation.

EXAMPLES

EXAMPLE 1

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH FIBRONECTIN.

The coating apparatus consisted of an overhead stirrer (Fisher Scientific) orientated horizontally. A conical stainless steel head was attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft was pulled up onto the conical head until held firmly. The other end was attached to a clip-swivel device that held the graft in a horizontal position, but allowed the graft to rotate along its axis. The stirrer was then set to rotate at 30 rpm so that the whole graft rotated along the horizontal axis at this speed. A 1% (w/w) fibronectin (Calbiochem, San Diego, CA) solution in sterile water was prepared. Two hundred microlitres of this solution was slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotated. The fibronectin was then dried under a stream of nitrogen as the graft continued to rotate. When dry, the
30 graft was removed, turned around and the other end of the graft coated in the same

manner. Using this method a flexible ring of fibronectin was deposited on both ends of the graft without compromise of the physical characteristics of the graft.

EXAMPLE 2

5 COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH POLY-L-LYSINE.

The coating apparatus consisted of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head was attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft was pulled up onto the conical head until held firmly. The other end was attached to a clip-swivel device that held the graft 10 in a horizontal position, but allowed the graft to rotate along its axis. The stirrer was set to rotate at 30 rpm so that the whole graft rotated along the horizontal axis at this speed. A 1% (w/w) poly-L-Lysine (Sigma, St. Louis, MO) solution in sterile water was prepared. Two hundred microlitres of this solution was slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period 15 of 2 minutes as the graft rotated. The poly-L-Lysine was then dried under a stream of nitrogen as the graft continued to rotate. When dry, the graft was removed, turned around and the other end of the graft coated in the same manner. Using this method a flexible ring of poly-L-Lysine was deposited on both ends of the graft without compromise of the physical characteristics of the graft.

20

EXAMPLE 3

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH N-CARBOXYBUTYL CHITOSAN.

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 25 1% (w/w) n-carboxybutyl chitosan (Carbomer, Westborough, MA) solution in sterile water is prepared. Two hundred microlitres of this solution is slowly pipetted as a 3 30 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head

over a period of 2 minutes as the graft rotates. The n-carboxybutyl chitosan is dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end coated in the same manner. Using this method a flexible ring of n-carboxybutyl chitosan is deposited on both ends of the graft

5 without compromise of the physical characteristics of the graft.

EXAMPLE 4

COATING OF ANATOMIC AORTIC GRAFTS WITH BROMOCRIPTINE IN POLY(ETHYLENE VINYL ACETATE).

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 10 4.5% w/w solution of EVA (60/40 ratio ethylene to vinyl acetate) (Polysciences USA) is prepared in dichloromethane. Bromocriptine mesylate (Sigma, St. Louis, MO) is dissolved/suspended in this solution at 5 mg/ml. Two hundred microlitres of this 15 solution is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The 20 EVA/bromocriptine is dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end of the graft coated in the same manner. Using this method a flexible ring of EVA/bromocriptine is deposited on both ends of the graft without compromise of the physical characteristics of the 25 graft.

25

EXAMPLE 5

PREPARATION OF INFLAMMATORY MICROCRYSTALS (MONOSODIUM URATE MONOHYDRATE AND CALCIUM PYROPHOSPHATE DIHYDRATE).

Monosodium urate monohydrate (MSUM) microcrystals were grown. A 30 solution of uric acid (certified A.C.S., Fisher Scientific) and sodium hydroxide at 55°C and pH 8.9 was left to stand overnight at room temperature. The crystals were rinsed

several times with cold (4°C) distilled water and dried at 60°C for 12 hours in a circulating hot-air oven (Fisher, Isotemp).

Triclinic calcium pyrophosphate dihydrate (CPPD) crystals were prepared as follows. A 250 ml beaker containing 103 ml distilled water was heated in a 5 water bath to 60 ± 2°C, and stirred constantly with a Teflon-coated stir bar. The stirring was slowed and 0.71 ml of concentrated hydrochloric acid and 0.32 ml of glacial acetic acid were added, followed by 0.6 g of calcium acetate (Fisher Certified Reagent). A 150 ml beaker containing 20 ml distilled water was heated to 60°C in the water bath, and 0.6 g calcium acetate added. The rate of stir was increased in the 250 ml beaker, 10 and 2 g of calcium acid pyrophosphate added rapidly. When the CaH₂P₂O₇ had nearly all dissolved, the rate of stirring was reduced for 5 minutes, then over a period of 15 seconds, the contents of the small beaker were poured into the large beaker with vigorous stirring. In the preparation of subsequent batches, a minute amount of triclinic CPPD crystals was added to the large beaker as seed material. Stirring was 15 discontinued, leaving a white gel. This was allowed to remain undisturbed in the cooling water bath. The pH of the supernatant was always less than 3.0. The gel collapsed as CPPD crystals formed in 24 hours. The crystals were washed in distilled water 3 times, washed in ethanol then acetone, and air dried.

20

EXAMPLE 6

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH INFLAMMATORY MICROCRYSTALS (MONOSODIUM URATE MONOHYDRATE OR CALCIUM PYROPHOSPHATE DIHYDRATE).

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the 25 stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until it is held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 4.5% w/w solution of EVA (60/40 ratio ethylene to vinyl acetate) 30 (Polysciences USA) is prepared in dichloromethane. Inflammatory microcrystals (MSUM or CPPD) are ground in a pestle and mortar to a particle size of 10 to 50

micrometers and suspended in the solution at 5 mg/ml. Two hundred microlitres of this suspension is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The EVA/microcrystals is then dried under a stream of nitrogen as the graft continues to
5 rotate. When dry, the graft is removed, turned around and the other end of the graft coated in the same manner. Using this method a flexible ring of EVA/microcrystals is deposited on both ends of the graft without compromise of the physical characteristics of the graft.

10

EXAMPLE 7

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH INFLAMMATORY MICROCRYSTALS (MONOSODIUM URATE MONOHYDRATE OR CALCIUM PYROPHOSPHATE DIHYDRATE).

A 1% w/w solution of Polyurethane (PU) (Medical grade, Thermomedics, Woburn, MA) is prepared in dichloromethane. Inflammatory microcrystals are ground in a pestle and mortar to a particle size of 10 to 50 micrometers and suspended in the solution at 2 mg/ml. Immediately prior to surgical insertion each end of the graft is inserted into the shaken suspension to a depth of approximately 5 mm for 2 seconds. The graft is air-dried (gently rotated by hand for 3 minutes). Using this method a flexible ring of EVA/microcrystals is deposited on both
20 ends of the graft without compromise of the physical characteristics of the graft.

EXAMPLE 8

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH BROMOCRIPTINE IN POLYURETHANE.

A 1% w/w solution of Polyurethane (PU) (Medical grade, Thermomedics, Woburn, MA) is prepared in dichloromethane. Bromocriptine mesylate (Sigma, St. Louis, MO) at 5% w/w to PU is dissolved/suspended in this solution. The solution is placed in a 5 ml Fisher TLC atomizer (Fisher Scientific). Prior to surgery the graft is suspended vertically in a fume hood and 1 ml of the solution sprayed (using nitrogen propellant) onto the bottom 1 cm of the graft by revolving the graft through
25 360 degrees. The graft is dried for 2 minutes and then the other end of the graft is sprayed in a similar manner. The graft is then further air dried (gently rotated by hand
30

for 3 minutes). Using this method a flexible ring of bromocriptine/PU is deposited on both ends of the graft without compromise of the physical characteristics of the graft. It is envisaged that ultimately a bromocriptine/PU solution in DCM would be available to the surgeon in the form of a small aerosol can for the above procedure.

5

EXAMPLE 9

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH INFLAMMATORY MICROCRYSTALS (MONOSODIUM URATE MONOHYDRATE OR CALCIUM PYROPHOSPHATE DIHYDRATE).

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until it is held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 4.5% w/w solution of Poly (lactide co-glycolide) (85:15) (IV 0.61) (Birmingham Polymers, Birmingham, AL) blended with methoxypolyethylene glycol 350 (MePEG 350) (Union Carbide, Danbury, CT) in a ratio of 80:20 w/w (PLGA:MePEG) is prepared in dichloromethane. Inflammatory microcrystals are suspended in the solution at 5 mg/ml. Two hundred microlitres of this suspension is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The PLGA/MePEG/inflammatory crystals are then dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end of the graft coated in the same manner. Using this method a flexible ring of PLGA/MePEG/microcrystals is deposited on both ends of the graft without compromise of the physical characteristics of the graft.

EXAMPLE 10

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH SOLVENTS, SUCH AS ETHANOL OR CHLOROFORM.

A 1% w/w solution of Polyurethane (PU) (Medical grade, 5 Thermomedics, Woburn, MA) is prepared in chloroform and stored until needed. Immediately prior to surgical insertion each end of the graft is dipped in the solution to a depth of approximately 5 mm for 2 seconds. The graft is immediately inserted into the animal before the polymer had fully dried. Using this method a flexible ring of PU containing significant amounts of chloroform is located at the required thrombogenic 10 site without compromise of the physical characteristics of the graft. Alternatively, the PU can be dissolved at 1% (w/v) in a solution of chloroform: ethanol (80:20) to enable ethanol to be deposited at the site.

EXAMPLE 11

15 COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH ANGIOTENSIN 2

ENCAPSULATED IN POLYETHYLENE GLYCOL (PEG)

1.8 grams of Polyethylene glycol 1475 (Union Carbide, Danbury, CT) is placed in a flat-bottomed 20 ml glass scintillation vial and warmed to 50°C to melt the PEG in a water bath, 200 mg of glycerol (Fisher Scientific) is added. 2 mg of 20 angiotensin 2 (Sigma, St. Louis, MO) is weighed into the vial and blended/dissolved into the melted PEG at 50°C. The vial is angled at 10 degrees in a water bath by use of a clamp. Each end of the graft is rotated in the molten formulation, so that a ring of material is deposited on the bottom 5 mm of the exterior surface of the graft. The graft is then cooled and stored at 4°C until use. Alternatively, to enable dipping immediately 25 prior to surgery the PEG/angiotensin mixture is stored at 4°C until use. Immediately prior to surgery, the vial of PEG/angiotensin is warmed to 50°C for 2 minutes to melt and the graft is coated as described above.

EXAMPLE 12

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH TRANSFORMING GROWTH FACTOR- β (TGF- β) IN CROSSLINKED HYALURONIC ACID.

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 1% solution of hyaluronic acid (HA) (Sodium salt, Sigma, St. Louis, MO) in water, containing 30% glycerol (w/w to HA) (Fisher Scientific) and 8 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) (Sigma, St. Louis, MO) is prepared by dissolution overnight. TGF- β (Calbiochem, San Diego, CA) is dissolved at 0.01 mg/ml in this solution. Two hundred microlitres of this solution is slowly pipetted as a 3 mm wide ring located 5 mm from the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The HA/glycerol/TGF- β solution is dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end coated in the same manner. Using this method a flexible ring of HA/glycerol/TGF- β is deposited on both ends of the graft without compromise of the physical characteristics of the graft.

EXAMPLE 13

COATING OF INTRA-ANATOMIC AORTIC GRAFTS WITH FIBROBLAST GROWTH FACTOR (FGF) IN CROSSLINKED CHITOSAN.

The coating apparatus consists of a Fisher overhead stirrer orientated horizontally. A conical stainless steel head is attached to the revolving chuck of the stirrer. One end of the intra-anatomic aortic graft is pulled up onto the conical head until held firmly. The other end is attached to a clip-swivel device that holds the graft in a horizontal position, but allows the graft to rotate along its axis. The stirrer is set to rotate at 30 rpm so that the whole graft rotates along the horizontal axis at this speed. A 1% solution of chitosan (Medical grade, Carbomer, Westborough, MA) in dilute acetic

acid (pH 5), containing 30% glycerol (w/w to chitosan) (Fisher Scientific) and 0.5% glutaraldehyde (Sigma, St. Louis, MO) is prepared by dissolution overnight. FGF (Calbiochem, San Diego, CA) is dissolved at 0.01 mg/ml in this solution. Two hundred microlitres of this solution is slowly pipetted as a 3 mm wide ring located 5 mm from
5 the end of the graft fixed in the conical steel head over a period of 2 minutes as the graft rotates. The chitosan/glycerol/FGF solution is dried under a stream of nitrogen as the graft continues to rotate. When dry, the graft is removed, turned around and the other end coated in the same manner. Using this method a flexible ring of chitosan/glycerol/FGF is deposited on both ends of the graft without compromise of the
10 physical characteristics of the graft.

EXAMPLE 14

SCREENING PROCEDURE FOR ASSESSMENT OF PERIGRAFT REACTION

Large domestic rabbits are placed under general anesthetic. Using
15 aseptic precautions, the infrarenal abdominal aorta is exposed and clamped at its superior and inferior aspects. A longitudinal arterial wall arteriotomy is performed and a 2 millimeter diameter, 1 centimeter long segment of PTFE graft is inserted within the aorta and the proximal and distal aspect of the graft is sewn so that the entire aortic blood flow is through the graft which is contained in the abdominal aorta in the manner
20 of open surgical abdominal aortic repair in humans (except that no aneurysm is present in this model). The aortotomy is then surgically closed and the abdominal wound closed and the animal recovered.

The animals are randomized to receive standard PTFE grafts or grafts of which the middle 1 cm is coated alone circumferentially with nothing, or with an agent
25 that induces a vessel wall reaction or adhesion between a stent graft and vessel wall alone or contained in a slow release, polymer such as polycaprolactone or polylactic acid.

The animals are sacrificed between 1 and 6 weeks post surgery, the aorta is removed en bloc and the area in relation to the graft is grossly examined for adhesive
30 reaction. Any difference in morphology or histology of the vessel wall from portions of

the artery which contain no graft, portion which contain graft without coating, and portion which contained graft with coating is noted.

EXAMPLE 15

5 ANIMAL ABDOMINAL AORTIC ANEURYSM MODEL

Pigs or sheep are placed under general anesthetic. Using aseptic precautions the abdominal aorta is exposed. The animal is heparinized and the aorta is cross clamped below the renal arteries and above the bifurcation. Collaterals are temporarily controlled with vessel loops or clips that are removed upon completion of 10 the procedure. A longitudinal aortotomy is created in the arterial aspect of the aorta, and an elliptical shaped patch of rectus sheath from the same animal is sutured into the aortotomy to create an aneurysm. The aortic clamps from the lumbar arteries and collaterals are removed and the abdomen closed. After 30 days, the animal is reanesthetized and the abdominal wall again opened. A cutdown is performed on the 15 iliac artery and through this, a stent graft is positioned across the infrarenal abdominal aorta aneurysm extending from normal infrarenal abdominal aorta above to normal infrarenal abdominal aorta below the surgically created aneurysm and the device is released in a conventional way.

Animals are randomized into groups of 5 receiving uncoated stent grafts, 20 stent graft containing slow release polymer alone, and stent graft containing a biologically active or irritative substance as determined by the previously mentioned screening exam. After closure of the arteriotomy and of the abdominal wound, the animal is allowed to recover. At 6 weeks and 3 months post stent graft insertion, the animal is sacrificed and the aorta removed en bloc. The infrarenal abdominal aorta is 25 examined for evidence of histologic reaction and perigraft leaking.

From the foregoing, it is appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We claim:

1. A stent graft, comprising an endoluminal stent and a graft, wherein said stent graft releases an agent which induces the *in vivo* adhesion of the stent graft to vessel walls.
2. A stent graft, comprising an endoluminal stent and a graft, wherein said stent graft induces or accelerates an *in vivo* fibrotic reaction causing said stent graft to adhere to vessel walls.
3. The stent graft according to claim 1 or 2 wherein said stent graft releases a vessel wall irritant.
4. The stent graft according to claim 3 wherein said vessel wall irritant is selected from the group consisting of talcum powder, metallic beryllium, and silica.
5. The stent graft according to claim 1 or 2 wherein said stent graft releases a component of extracellular matrix.
6. The stent graft according to claim 1 wherein said agent is fibronectin.
7. The stent graft according to claim 1 or 2 wherein said stent graft releases polylysine, or, ethylenevinylacetate.
8. The stent graft according to claim 1 or 2 wherein said stent graft releases an inflammatory cytokine selected from the group consisting of TGF β , PDGF, VEGF, bFGF, TNF α , NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone.
9. The stent graft according to claim 1 wherein said agent is an adhesive.

10. The stent graft according to claim 9 wherein said adhesive is cyanoacrylate.

11. The stent graft according to claim 1 or 2 wherein said stent graft is bifurcated.

12. The stent graft according to claim 1 or 2 wherein said stent graft is a tube graft.

13. The stent graft according to claim 12 wherein said stent graft is cylindrical.

14. The stent graft according to claim 1 or 2 wherein said stent graft is self-expandable.

15. The stent graft according to claim 1 or 2 wherein said stent graft is balloon-expandable.

16. The stent graft according to claim 1 or 2 wherein the distal ends of said stent graft are adapted to release an agent which induces adhesion.

17. The stent graft according to claim 1 or 2 wherein the entire body of said stent graft is adapted to release an agent that induces adhesion.

18. The stent graft according to claim 1 or 2, further comprising a coating which delays the onset of adhesion or fibrosis.

19. The stent graft according to claim 1 wherein said agent is first activated from a previously inactive agent to an active agent.

20. The stent graft according to claim 1 wherein said stent graft is activated from a previously inactive stent graft to a stent graft that induces or accelerates an *in vivo* fibrotic reactions.

21. A method for treating patient having an aneurysm, comprising delivering to a patient a stent graft according to claim 1 or 2, such that risk of rupture of the aneurysm is reduced.

22. The method according to claim 21 wherein said aneurysm is an abdominal aortic aneurysm.

23. The method according to claim 21 wherein said aneurysm is a thoracic aortic aneurysm.

24. The method according to claim 21 wherein said aneurysm is an iliac aortic aneurysm.

25. A method for bypassing disease within a vessel, comprising delivering to a patient a stent graft according to any one of claims 1 to 20, such that vessel contents bypass said diseased portion of said vessel.

26. A method for creating communication between an artery and a vein, comprising delivering to a patient a stent graft according to any one of claims 1 to 20, such that a passageway is created between said artery and vein.

27. A method for creating communication between a first vein and a second vein, comprising delivering to a patient a stent graft according to any one of claims 1 to 20, such that a passageway is created between said first and second veins.

28. The method according to any one of claims 21, 25, 26, or, 27 wherein said stent graft is delivered into a patient in a constrained form, and self-expands into place after release of a constraining device.

29. The method according to any one of claims 21, 25, 26, or, 27 wherein said stent graft is delivered to said patient by balloon catheter.

30. A method of manufacturing an adhesive stent graft, comprising coating a stent graft with an agent which induces adhesion of the stent graft to vessel walls.

31. The method according to claim 30 wherein said stent graft is coated by spraying, dipping, or wrapping said stent graft with said agent.

32. The method according to claim 30 wherein said agent further comprises a polymer.

33. The method according to claim 30 wherein said agent is a vessel wall irritant.

34. The method according to claim 30 wherein said agent is an inflammatory cytokine.

35. The method according to claim 30 wherein said agent is an inflammatory crystal.

36. The method according to claim 30 wherein said agent is bFGF.

1/1




Fig. 1




Fig. 2

INTERNATIONAL SEARCH REPORT

Inte	lational Application No
PCT/CA 99/01237	

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7	A61L31/10	A61L31/16 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7	A61L	A61F
-------	------	------

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 06792 A (SCIMED LIFE SYSTEMS INC) 15 April 1993 (1993-04-15) page 22, line 10 - line 32 page 23, line 1 - line 2	1-36
X	WO 91 17789 A (STACK RICHARD S ;CLARK HOWARD G III (US); WALKER WILLIAM F (US)) 28 November 1991 (1991-11-28) page 21, line 18 - line 34; example	1-36
X	WO 97 46590 A (GORE ENTERPRISE HOLDINGS INC) 11 December 1997 (1997-12-11) claims; examples 54-58	1,2,7
X	EP 0 850 651 A (SCHNEIDER USA INC) 1 July 1998 (1998-07-01) column 4, line 16 - line 41	1,2,5-8, 11-36
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	14 April 2000	Date of mailing of the international search report

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	ESPINOSA, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/01237

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 383 928 A (SCOTT NEAL A ET AL) 24 January 1995 (1995-01-24) column 5, line 34 - line 54 _____	1,2,5-8, 11-36
X	WO 94 13268 A (KAPLAN AARON V) 23 June 1994 (1994-06-23) page 12, line 19 - line 36 _____	1,2,5-8, 11-36
X	WO 94 01483 A (COLLAGEN CORP) 20 January 1994 (1994-01-20) claims _____	1,2,5-8, 11-36
X	WO 97 46268 A (COOK INC ;FISCHER FRANK J JR (US)) 11 December 1997 (1997-12-11) page 10, line 10 - line 31 page 11, line 1 - line 21 _____	1,2,5-8
X	EP 0 623 354 A (MEDTRONIC INC) 9 November 1994 (1994-11-09) page 4, line 39 - line 42 _____	1,2,5-8
X	EP 0 734 721 A (ADVANCED CARDIOVASCULAR SYSTEM) 2 October 1996 (1996-10-02) column 4, line 33 - line 58 _____	1,2,5-8
X	US 5 725 568 A (HASTINGS ROGER N) 10 March 1998 (1998-03-10) column 2, line 30 column 3, line 1 - line 3 _____	1,2,5-11

INTERNATIONAL SEARCH REPORT

International Search Report No.

PCT/CA 99/01237

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: - because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 21-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No

PCT/CA 99/01237

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9306792	A 15-04-1993	US 5968092 A			19-10-1999
		US 5464450 A			07-11-1995
		US 5551954 A			03-09-1996
		US 5500013 A			19-03-1996
		US 5769883 A			23-06-1998
WO 9117789	A 28-11-1991	AU 653159 B			22-09-1994
		AU 8001891 A			10-12-1991
		EP 0528993 A			03-03-1993
		EP 0737453 A			16-10-1996
		JP 5509008 T			16-12-1993
		US 5527337 A			18-06-1996
WO 9746590	A 11-12-1997	US 5914182 A			22-06-1999
		US 5874165 A			23-02-1999
		AU 3229797 A			05-01-1998
		EP 0910584 A			28-04-1999
		US 5897955 A			27-04-1999
EP 0850651	A 01-07-1998	CA 2225096 A			20-06-1998
		JP 10192413 A			28-07-1998
		US 5980972 A			09-11-1999
US 5383928	A 24-01-1995	NONE			
WO 9413268	A 23-06-1994	US 5342348 A			30-08-1994
		AU 5616894 A			04-07-1994
WO 9401483	A 20-01-1994	US 5324775 A			28-06-1994
		US 5328955 A			12-07-1994
		US 5308889 A			03-05-1994
		US 5292802 A			08-03-1994
		AU 677789 B			08-05-1997
		AU 4662093 A			31-01-1994
		EP 0648239 A			19-04-1995
		JP 8502082 T			05-03-1996
		US 5510418 A			23-04-1996
		US 5470911 A			28-11-1995
		US 5476666 A			19-12-1995
		US 5510121 A			23-04-1996
		US 5565519 A			15-10-1996
		US 5413791 A			09-05-1995
		US 5475052 A			12-12-1995
		US 5446091 A			29-08-1995
		US 5527856 A			18-06-1996
		US 5614587 A			25-03-1997
		US 5550188 A			27-08-1996
		US 5643464 A			01-07-1997
		US 5936035 A			10-08-1999
		US 5800541 A			01-09-1998
		US 5786421 A			28-07-1998
		US 5744545 A			28-04-1998
WO 9746268	A 11-12-1997	AU 3294497 A			05-01-1998
		EP 0906129 A			07-04-1999
EP 0623354	A 09-11-1994	US 5464650 A			07-11-1995
		JP 8033718 A			06-02-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/01237

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
EP 0623354 A		US	5837008	A	17-11-1998
		US	5679400	A	21-10-1997
		US	5624411	A	29-04-1997
		US	5776184	A	07-07-1998
		US	5824048	A	20-10-1998
EP 0734721 A	02-10-1996	US	5605696	A	25-02-1997
		AU	4825696	A	10-10-1996
		CA	2172187	A	01-10-1996
		JP	8266637	A	15-10-1996
US 5725568 A	10-03-1998	NONE			